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Abstract 
Rotavirus is responsible for the death of many children annually, and current 
vaccines have lower efficiency in developing countries. A reverse translated 
consensus gene sequence of the rotavirus VP6 cloned into a pET-28a(+) plasmid 
was used to transform BL21 and KRX Escherichia coli cells. Optimal expression of 
soluble protein was induced in KRX cells by adding 0.05% L-rhamnose and 0.0001 
M IPTG, with an incubation temperature of 25ºC for 6 h. VP6 was purified by 
combining anion exchange chromatography followed by affinity chromatography. 
Far-UV circular dichroism and intrinsic fluorescence were used as probes to assess 
the native structure of VP6 and structural in the presence of a denaturant, high 
sodium chloride concentrations and varying temperatures. The 0.2 M sodium 
chloride had an impact on the VP6’s tertiary structure and also influenced the 
proteins conformational changes as detected during thermal unfolding to 90ºC. 
Although treatment with 3 M urea showed tertiary structural changes no secondary 
structural loss occurred due to the presence of a denaturant. 
 
 
 
 
 
 
Key words: chromatography, circular dichroism, Escherichia coli, fluorescence, 
plasmid, protein conformation, protein expression, purification, rotavirus, VP6. 
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Chapter 1: Introduction 
Gastroenteritis is responsible for causing 2.1 million deaths in children every year 
globally (Parashar et al. 2006), and 683,100 deaths in 2011 (Lanata et al. 2013), 
even though there is a reduction in gastroenteritis related mortality, diarrhoea 
remains the second leading cause of death in children under the ages of five around 
the world (Walker et al. 2012). A number of agents have been identified as causing 
gastroenteritis namely, enteric adenovirus, calicivirus, norovirus and astrovirus, but 
the most commonly known virus associated with severe gastroenteritis in young 
children is rotavirus (RV) (Wilhelmi et al. 2003). 
Rotaviruses are known to invade the intestine via the faecal-oral route (Ward et al. 
1991), and are capable of causing long-term infection owing to their ability to survive 
on dry inanimate objects (Sattar et al. 1986). Of all the annual deaths occurring 
worldwide due to diarrhoea-related gastroenteritis in infants, RV is responsible for at 
least 453,000 (21.5%) of the deaths (Parashar et al. 2003; Tate et al. 2012). In 
developing countries the mortality rate in infants and young children was found to be 
higher than in developed countries, with deaths estimated to be about 500,000 every 
year (Cunliffe et al. 2002); 230,000 of these deaths occurring in Africa (Mwenda et 
al. 2010). 
Rehydration with water or dextrose-saline (in severe water loss) is often required to 
prevent dehydration-related death (Atherly-John et al. 2002; Kirkwood et al. 2011). 
There are vaccines that are administered to reduce the severity of RV gastroenteritis 
(i.e. RotaTeqTM and Rotarix®). However virus-like proteins (VLP) or protein-based, 
non-replicative particles have been targeted as possible vaccine candidates with 
promising results and are more cost effective (Parez, 2008; Shoja et al. 2014). 
 
1.1. Rotavirus structure and genome composition 
Rotaviruses belong to the Reoviridae family and they consist of eleven double-
stranded ribonucleic acid (dsRNA) enclosed within layers of proteins (Gorziglia et al. 
1990). Rotaviruses are non-enveloped, triple-layered viruses with a wheel-like shape 
and spoke-like protrusions made up of VP4 on the outer surface, and with VP7 
forming the smooth outer layer (Figure 1-1) (Prasad & Estes, 1997). VP4 is cleaved 
by trypsin into VP8 and VP5 during the maturation stage (Patton et al. 1997).  
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Figure 1-1: Rotavirus structure and composition 
The figure represents the spherical structure of rotavirus showing VP4 (or VP8 and VP5 after 
cleavage by trypsin) forming the outer spikes, VP7 forming the smooth outer layer of the 
virus.VP6 dominates the middle layer of the virus, and VP2 acts as the inner layer that 
encloses VP1, VP3 and the dsRNA genome segments located in the core of the virus. 
  
VP8 
VP5 
VP4 
VP6 
VP2 
dsRNA 
VP1 and VP3 
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After VP4 is cleaved by 
trypsin 
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The second or intermediate layer is made up of VP6 which covers an inner layer 
made up of VP2, this layer encloses two enzymes (VP1 and VP3) and 11 dsRNA 
segments (Zeng et al. 1997) (Figure 1-1).  
There are also non-structural proteins (NSPs) that are named from NSP1 to NSP5. 
These proteins are synthesized in infected cells and do not form part of the RV 
structure, but they assist in the replication and assembly of new RV virions (Crawford 
et al. 2001). Each of the 11 dsRNA segments encode either a VP or a NSP with the 
exception of segment number 11, which in some RV strains codes for two NSPs 
(NSP5 and NSP6) (Mascarenhas et al. 1997; Hu et al. 2012). Figure 1-2 depicts the 
migration pattern of the RV genome segments on a polyacrylamide gel along with 
the protein that each genome forms. 
 
1.2. Rotavirus replication cycle 
The RV capsid proteins help protect its viral genome, assist in host cell entry and 
initiate transcription of the viral genome (Jayaram et al. 2004). Rotavirus enters the 
cell via endocytosis (Sánchez-San et al. 2004; Gutiérrez. et al. 2010), and the outer 
layer is removed forming a double layered particle (DLP) which triggers endogenous 
transcriptase activity (Crawford et al. 2001) which enable the virus to release its 
capped transcripts through VP6 aqueous channels for translation (Lawton et al. 
1997)a. The viral genome is translated into six structural proteins (VP1 to VP4, VP6, 
and VP7); and six non-structural proteins (NSP1 to NSP6). The proteins are 
necessary for the assembly of new viral particles (Patton & Spencer, 2000). The 
NSPs adapt and modify the cellular machinery by antagonising the interferon (IFN) 
activity; shutting down the host’s cell translation; forming viroplasm inclusion bodies 
for viral replication and assembly; and assisting in the structural orientation the VPs 
(Fabbretti et al. 1999). The translated VP2 and VP6 form a double-layered RV 
particle which enters the rough endoplasmic reticulum (RER) acquiring VP4, VP7 
and NSP4 that were also translated and assembled on the membrane of the RER. 
The newly formed viral particle undergoes intermediate membrane displacement by 
VP7, thus forming a triple-layered RV particle. The viral particle leaves the cell by 
exocytosis or cell lysis. Once the RV has exited the cell, trypsin cleaves VP4 into 
VP5 and VP8, forming a mature RV particle (Lawton et al. 1997)b that is capable of 
infecting other cells (Figure 1-3).  
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Figure 1-2: Electrophoresis gel migration pattern of 11 rotavirus dsRNA genome 
segments and the proteins that they form 
Rotavirus gene segments are labelled 1 to 11 on the basis of their size with gene segment 1 
having the highest number of base pairs and gene segment 11 with the least number of 
base pairs (Rixon et al. 1984).  
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Figure 1-3: Rotavirus replication cycle 
The figure is an author drawn image adapted from ViralZone-ExPASy, (2014) (https://viralzone.expasy.org). Rotavirus starts by attaching to the 
host’s cell membrane (1), and is engulfed after interacting with membrane receptors (2). It escapes the endosome by shedding its outer layer 
and becoming a double layered particle (3). The now double layered particle starts to release viral genome transcripts from aqueous channels 
found on the now exposed VP6 layer (4). The RNA is translated forming VPs and NSPs necessary for assembling new virions (5). New double 
layered virions are formed from translated VPs with the assistance of NSP2 and NSP5 (7). The newly formed virions undergo lipid membrane 
displacement by VP7 (8) before escaping through the rough endoplasmic reticulum by exocytosis (9) (Trask et al. 2012). VP4 is cleaved by 
trypsin into VP5 and VP8 to complete the maturation of rotavirus (10). 
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1.3. Rotavirus capsid proteins and non-structural proteins 
1.3.1. Outer layer proteins 
The proteins that form the outer most layer of RV are VP7 and VP4 (Figure 1-1) 
(González et al. 1998). These two proteins help protect the virus and assist with host 
cell entry (Zárate et al. 2003; Trask et al. 2012). VP7 is a 37 kDa glycoprotein, and 
the VP7 layer is formed by 780 proteins (Nava et al. 2004; Coulson, 2012).  
VP4 is an 88 kDa protein that forms 60 dimers of spiky protrusions on the RV’s outer 
surface (González et al. 1998; Crawford et al. 2001). VP4 is cleaved into VP8 and 
VP5 by trypsin, an enzyme found in the digestive system of vertebrates (Espejo et al. 
1981; Graham et al. 2003).  
VP8 binds to mature enterocytes of the small intestine and initiates conformational 
changes that aid the interaction between VP5 and the host cell membrane to initiate 
phagocytosis of the virus into the cell (Graham et al. 2003; Settembre et al. 2011) 
(Figure 1-3). 
 
1.3.2. Middle layer protein 
The middle layer is dominated by 260 trimers of VP6 (Vieira et al. 2005). This protein 
has a major role in structural and functional organisation of RV as it is in direct 
contact with the outer layer (VP7) that is involved in cell entry; and the inner layer 
(VP2) that is involved in genomic RNA packaging. VP6 becomes exposed after VP4 
and VP7 are removed during cell entry (Figure 1-3). As a result the former triple-
layered virus becomes a double-layered virus (Lawton et al. 1997; Tihova et al. 
2001). This transition enables the virus to be transcriptionally active, allowing dsRNA 
strands to pass from the viral core through VP2 layer and then out through the VP6 
layer via a system of aqueous channels that penetrate VP6 and VP2 (Jayaram et al. 
2004). 
 
1.3.3. Inner core proteins 
The inner layer of RV is an icosahedral barrier formed by 60 dimers (120 molecules) 
of VP2 (González et al. 1998). This layer encloses the viral dsRNA genome 
segments, polymerase enzymes (VP1) and guanyltransferase methylases (VP3) 
(Crawford et al. 2001) (Figure 1-1). VP2 interacts with VP6 through aqueous 
channels that aid in transporting metabolites from the outside to the inside of the 
virus, and releasing dsRNA during replication (Zeng et al. 1998). 
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1.3.4. Non-structural proteins 
The NSPs carry out functions during the viral replication cycle and morphogenesis 
(Crawford et al. 2001). Non-structural protein 2 is a 35 kDa multimeric protein with 
nucleoside triphosphatase and helix-destabilizing activities (Taraporewala et al. 
2006). It’s role is to unwind the RV dsRNA (Silvestri et al. 2004). Non-structural 
protein 5 is a 12 kDa protein and was reported to interact with NSP2, VP1 and VP2 
during viral replication and assembly (Vitour et al. 2004). Non-structural protein 2 
and NSP5 are involved in the formation of a viroplasm necessary for viral replication 
and assembly inside the hosts’ intestinal cells (González et al. 1998). Non-structural 
protein 1 and NSP3 are released into the cytoplasm after translation, where they 
assist in ensuring successful cell invasion and translation by acting as IFN 
antagonists (role of NSP1); and shutting off host cell translation (role of NSP3) 
(Trask et al. 2012). NSP4 is a 20 kDa protein that is encoded by gene segment 10, 
and has three hydrophobic domains named H1 to H3 (Hu et al. 2012). The H3 
domain is considered to affect the calcium homeostasis by increasing intracellular 
calcium accompanied by release of chloride ions from the cells (Hyser et al. 2010). 
NSP4 also disrupts plasma membrane integrity which inhibits sodium absorption, 
thus, increasing sodium and chloride ions in the lumen and inducing diarrhoea 
(Ousingsawat et al. 2011). 
 
1.4. Rotavirus serotype and subgroup classification 
Rotaviruses are classified into G-serotypes based on the sequence of the 
glycoprotein VP7, and also into P-serotypes based on the sequence of the protease-
sensitive protein VP4 (Georges-Courbot et al. 1988). Group A rotaviruses (RVA) 
have at least 27 G-serotypes (G1 to G27) and 37 P-serotypes (P1 to P37) 
(Matthijnssens et al. 2011; Rotavirus Classification Working Group, 2013). The most 
common G and P-serotype combinations that are responsible for many RV infections 
in children globally are G1P1A[8], G2P1B[4], G3P1A[8], G4P1A[8]; serotypes 
G9P1A[8] and G12P1A[8] were later detected in high frequencies (Santos & 
Hoshino, 2005; Iturriza-Gomara et al. 2011). Developing countries in Africa, Asia and 
South America showed high frequencies of other genotypes including G5, G6 and 
G8 (Kang et al. 2013, Luchs & Timenetsky, 2014). 
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Rotaviruses are also classiﬁed into seven antigenically distinct groups (Group A to 
G) (Riepenhoff-Talty et al. 1996; Ward & McNeal, 2010). Group A, B, and C are 
infectious to both humans and animals, with group A being the most globally 
prevalent in humans (Geyer et al. 1996, Estes, 2001). There are also four subgroups 
of RVs namely, SGI, SGII, SGI/II, and SG non I/II which depends on the presence of 
I and II antigens (Estes & Cohen, 1989; Saif & Jiang, 1994). These group-specific 
and subgroup-specific sites for antigenic determination are founded on the type of 
immune reaction against VP6 (Tang et al. 1997). 
 
1.5. Structure of the VP6 protein 
The VP6 protein structure is organized into two distinct domains (Figure 1-4). The 
domains are represented as S and H, the S domain is comprised of β-sheets and the 
H domain contains eight α-helices which are formed from the first 150 amino acids of 
the N-terminus and 335-397 residues of the C-terminus (Mathieu et al. 2001). 
The amino acid sequence of RV VP6 is highly conserved among strains belonging to 
the same RV group, thus making VP6 a perfect candidate for determining RV group 
specificity and it is also known to be the most immunogenic protein of all the RV 
proteins (Estes & Cohen, 1989). Administering RV VP6 in rotavirus-infected mice as 
the only viral antigen was reported to have induced a protective immune response in 
the mice irrespective of the strain of the virus (Choi et al. 2000; Madore et al. 1999; 
Esteban et al. 2013). This indicates that vaccines that include VP6 antigen derived 
from RVA will help protect against infection by any RVA strain (Choi et al. 2002). 
When the RV’s outer capsid layer is removed during cell entry (Figure 1-3), VP6 
becomes exposed (Estes & Kapikian, 2007) explaining why there are antibodies 
(Abs) that are generated against VP6 in infected mice (Ward & McNeal, 2010). Since 
VP6 is important for RV replication, immunity induced against VP6 might interfere 
with the replication cycle of RV, thus making VP6 an appropriate vaccine candidate 
(Bertolotti-Ciarlet et al. 2003). Studies by Corthesy et al. (2006); Garaicoechea et al. 
(2008) and Aiyegbo et al. (2013) also proved that the anti-replicative ability of VP6 
antibodies against RV and approved protein-based vaccines are important as part of 
a safe and cost effective vaccine candidate in developing countries 
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S-domain      H-domain 
 
 
 
 
Tryptophan 
 
 
 
 
 
 
 
Figure 1-4: Ribbon diagram of the rotavirus VP6 protein 
The 3-D ribbon structure of a rotavirus VP6 monomer (Mathieu et al. 2001) was generated 
as part of the current study. The green region (S-domain) represents the beta–sheets, and 
the red region (H-domain) comprises mainly of alpha-helices. VP6 is comprised of five 
tryptophan residues (blue) (Mathieu et al. 2001). The Image was generated using PyMol 
[Delano Scientific, (2009)], from rotavirus VP6, PDB code: 1QHD. 
  
N-terminus C-terminus 
β-sheet α-helix 
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1.6. Rotavirus vaccines 
Current RV vaccines include Rotashield® (Wyeth–Lederle Vaccines, now a part of 
Pfizer), Rotateq® (Merck) and Rotarix (GlaxoSmithKline). All three of the vaccines 
have been approved by the food and drug administration (FDA) (Linhares et al. 
2008; Payne et al. 2010). Rotashield was suspended from use in USA since 1999, 
this was after it was thought to cause intussusception in vaccinated individuals 
(Program, 2001). Rotarix® is “a live human-attenuated RV vaccine” (De Vos et al. 
2004), and RotaTeqTM is a recombinant bovine-human vaccine (Heaton et al. 2005). 
Both of these vaccines have shown to be effective in developed countries (Ruiz-
Palacios et al. 2006, Vesikari et al. 2006; Snelling et al. 2011). However, the 
immunogenicity and effectiveness of these vaccines was shown to be lower in 
certain low-income countries of Africa (Cunliffe et al.2002; Sow et al. 2012); Asia 
(Zaman et al. 2010) and Central America (Patel et al. 2010). The reason for this is 
based on the difference in regional genotypes of the RV strains and serotypes that 
are different from the vaccine strains (Kirkwood et al. 2011; Bredell et al. 2016). This 
leaves not only a great demand to develop a cheaper RV vaccine candidate but also 
a demand for a vaccine that can protect against different RV strains, and a protein-
based vaccine can meet those demands (Maranga et al. 2002, Palomares & 
Ramirez, 2009). 
An efficient protein-based vaccine candidate has to have conserved epitopes, 
allowing the vaccine to be effective against different RVA strains (Parbhoo et al. 
2016). The challenge is that there are reports of continuous changes in RV strains 
that affect humans (Collins et al. 2015), these changes arise from inert-species 
transmission and RV genome reassortment (Nyaga et al. 2015).  
As indicated above, VP4 and VP7 form part of the outer protein layer for RV and 
have been thought to provide protective immunity due to the presence of neutralizing 
antibodies formed in the host after natural RV infection (Offit & Blavat, 1986; and 
Desselberger & Huppertz, 2011). However, these antibodies are not present after 
vaccination using attenuated viruses (Lappalainen et al. 2015), which renders the 
vaccine useless for raising immunity against VP4 and VP7 epitopes (Bertolotti-
Ciarlet et al. 2003; Aiyegbo et al. 2013). 
On the other hand, VP6 is found to be the best marker for RV vaccination as it 
generates serum immunoglobulin A (IgA) antibodies against VP6, particularly against 
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the conserved epitopes (Tang et al. 1997) this shows that a VP6-based vaccine will 
enable the vaccine to be effective against changing viral serotypes. 
 
1.7. Expression and purification of recombinant VP6 protein 
There are various expression systems used in protein production, i.e. yeast, fungi, 
insect, plant, animal, and bacterial cells that have been explored for production of 
proteins (Rosa, 1979; Dunn et al. 1983; Jonasson et al. 2002; Villaverde & Carrio, 
2003). 
Mason & Arntzen, (1995) and Johnson et al. (1997) reported plants to be a novel 
way of expressing “inexpensive” protein-based vaccine subunits. Engineered 
transgenic plants can express foreign proteins through integration of a foreign gene 
into the plant chromosome, which results in low protein yields (Mason & Arntzen, 
1995). 
Insect cell/baculovirus expression systems have been used for RV protein 
development which allows for high outputs, does not contain contaminants from 
mammalian sources and the baculovirus expression vectors are flexible and easy to 
handle (Maranga et al. 2002). However, it was later observed that the need for 
expression of recombinant proteins using insect cells poses challenges for vaccine 
bioprocessing and bioanalytics (Palomares & Ramírez, 2009). This was because 
large insect cells produce large tube structures that are difficult to isolate during size 
exclusion chromatography, and giving the possibility that other proteins are isolated 
along with the protein of interest, thus, contaminating a possible vaccine candidate. 
A study by Erk et al. (2003) found the presence of protease activity in the samples 
that were purified from a baculovirus-insect cell expression system, proving that 
there was incomplete purification. VP6 can take up different conformational 
structures including trimerization when exposed to different buffer pH or ionic 
strength (Estes et al. 1987; Lepault et al. 2001), formation of VLPs were observed 
when expression performed using plants, or during dual expression with VP2 using 
insect-cell expression systems (O’Brien et al. 2000). 
 
Escherichia coli cells are considered ideal for protein over-expression because they 
are low cost, and show rapid growth with high expression rate (Tabor & Richardson, 
1985; Amerein et al. 1995; Li et al. 2014). One of the important features of a 
bacterial expression system is the T7 RNA polymerase gene that is specific for a 
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conserved promoter region (Rosa, 1979). Inducers such as isopropyl β-D-1-
thiogalactopyranoside (IPTG) and L-rhamnose are required to initiate protein 
expression by enabling transcription to occur. Isopropyl β-D-1-thiogalactopyranoside 
causes the repressor to be released from the promoter sequence allowing 
transcription of genes from the lac operon to occur (Dunn et al. 1983). L-rhamnose 
induces the expression of the T7 promoter gene, which in-turn transcribes the gene 
of interest (Hartnett et al. 2006). Sørensen & Mortensen, (2005) reported that 80% of 
the proteins used for three-dimensional structures on the protein data bank (PDB) in 
2003 were expressed in E.coli cells. Escherichia coli cells transformed with pET 
plasmid were used in more than 90% of PDB proteins. This makes the combination 
of pET plasmid with E.coli cells the most popular protein expression system. 
Escherichia coli cells have also been reported to improve expression and purification 
of high amounts of recombinant proteins (Studier, 2005; Lobstein et al. 2012; Sethia 
et al. 2014), even though bacterial expression systems are reported to undergo 
irregular or incomplete folding processes that tend to render the protein to be 
presented as insoluble aggregates that are referred to as inclusion bodies (Hoffmann 
& Rinas, 2000; Schweder et al. 2002; Villaverde & Carrió, 2003; Fanhert et al. 2004). 
Improvement in expression of soluble proteins has been reported to be inconsistent 
because of the different protein species being expressed, the bacterial strain used or 
the expression system used (Thomas & Baneyx, 1996; Thomas & Baneyx, 1997). 
Expressing soluble proteins is ideal for easy and efficient purification because there 
is no requirement for pre-purification techniques.  
A study by Li et al. (2014) showed successful, separate expression of two RV capsid 
proteins (VP2 and VP6) in E.coli expression system. According to Li et al. (2014) the 
cells were incubated at 20°C for 6 h after inducing the cells with an unspecified 
concentration of IPTG. The low growth temperature is ideal for reducing stress within 
the expression system, and preventing aggregation of the expressed proteins (Lilie 
et al. 1998). The brief harvest time was stated to be important in reducing the 
presence of dead cells, thus, reducing the release of proteases from the dead cells 
(Chakrabarti et al. 2016). 
 
Chromatography was developed as a technique used to purify macromolecules 
following their interaction with an immobilised substrate (Cuatrecasas et al. 1968; 
Gerberding & Byers, 1998; Coskun, 2016). The commonly used protein purification 
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techniques are ion-exchange chromatography which binds molecules based on their 
charge, and can be selectively eluted off the charged resin by changes in pH or an 
increase in either sodium or chloride ions (Kopaciewicz et al. 1983; Jungbauer & 
Hahn, 2009). Another purification technique is affinity chromatography which binds 
molecules based on the type of immobile phase, whereby metals have an affinity to 
the imidazole ring of amino acids, and antibodies have affinity to a protein (antigen) 
(Magdeldin & Moser, 2012). There is also size exclusion chromatography where the 
biological molecules are separated by size when passed through a Sepharose 
column (Barth et al. 1996). 
 
Over-expressed target proteins from bacterial cell expression contain other bacterial 
cellular proteins and sometimes preparative purification measures are required such 
as precipitation with ammonium sulphate to salt-out the target protein before loading 
the protein sample on a column (Oldfield et al. 1990; Jiang et al. 2004). Salting-in 
proteins is when the increase in salt in a protein solution increases the solubility of 
the proteins, further increase in salt may cause the proteins to precipitate due the 
reduced interaction of the water molecules to the protein, and this is referred to as 
salting-out (Green & Hughes, 1955; Wingfield, 2001). 
Uhlén et al. (1992) reported that over-expressed target proteins are best expressed 
linked to a fused affinity tag because it helps in purifying the target protein after 
expression, and fusion tags do not affect the biological or biochemical activity of the 
expressed protein. Studies that expressed their target proteins along with a HisTag 
usually use a denaturant to ensure that the tag is exposed. 
A study by Choi et al. (2002) employed a method by Jarrett and Foster which 
involved cloning the VP6 gene into pMAL/c2X plasmid and using it to transform 
E.coli cells which were thereafter lysed and centrifuged to separate the insoluble 
proteins in the pellet from the soluble fraction in the supernatant. The proteins were 
denatured using 8 M urea to unfold proteins that have been misfolded and 
aggregated during expression, the proteins were refolded before conducting affinity 
chromatography. Badillo-Godinez et al. (2015) successfully purified VP6 using 
affinity chromatography (Nickel resin) with chemical denaturants to assure the affinity 
tag was not folded into the protein structure. 
 
14 
 
1.8. Aims and objectives 
The principle aims of this study were to optimise the over-expression and purification 
of soluble RV VP6, and to then characterise the expressed VP6 using various 
spectroscopic techniques. Achieving these aims required addressing the following 
objectives: 
 To transform the KRX and BL21 bacterial expression cells with recombinant 
VP6-pET-28a(+) plasmid.  
 To compare the two bacterial expression systems in terms of their ability to 
over-express soluble VP6 when induced with different inducer concentrations, 
post-induction time and temperature. 
 To purify VP6 using liquid chromatography techniques. 
 To use spectroscopic techniques to determine protein concentration, native 
structure and structural changes of VP6 in the presence of urea, high sodium 
chloride concentrations and under varying temperatures. 
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Chapter 2: Experimental procedure 
2.1. Materials 
The VP6 gene was synthesised, then cloned at the Nde I and BamH I restriction 
sites of the pET-28a(+) plasmid by Genscript® (China). Kanamycin and IPTG were 
purchased from Separations (Johannesburg, South Africa). The BL21 (DE3) cells 
and KRX E.coli cells (Promega) were purchased from Anatech (Johannesburg, 
South Africa). The SDS-PAGE molecular weight marker (MWM) was purchased from 
Thermo Fisher Scientific (United States of America). The HisTrap and HiPrep nickel-
Sephacryl prepacked columns, the DEAE-Sepharose beads and imidazole were 
purchased from Sigma-Aldrich (United States of America). All other chemicals were 
of analytical grade. 
 
2.2. Bioinformatics  
The VP6 gene used for this study was selected by searching the National Center for 
Biotechnology Information (NCBI) database (https://www.ncbi.nlm.nih.gov/) for full 
length (397 amino acids) RVA VP6 peptide sequences. A total of 130 full length 
peptide sequences were randomly selected from different countries reported from 
2005 to 2010. The obtained VP6 peptide sequences were used to generate a single 
consensus VP6 peptide strand (Figure 2-1) by using CLC genomics workbench 
v3.6.1 software (CLC Bio USA, Cambridge, MA).  
The consensus peptide sequence was reverse translate into a gene sequence using 
ExPASy, reverse translation tool (SIB Bioinformatics Resource Portal) 
(https://www.expasy.org/resources/search). 
The VP6 gene sequence was then sent to GenScript for synthesis and cloning into a 
pET-28a(+) plasmid cloned at the Nde I and BamH I restriction sites. The plasmid 
carried HisTag sites which are comprised of nucleotides sequences that code for 6 
histidine amino acids. One of the HisTag site was located on the N-terminal 
(incorporated by the Nde I restriction enzyme), and the other was located on the C-
terminal (incorporated by cleaving using the BamH I restriction enzyme) (Figure 2-2) 
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Figure 2-1: The resultant VP6 consensus sequence 
The resultant consensus protein sequence was generated from 130 full length RVA VP6 
peptide sequences. The five tryptophan residues are underlined and highlighted in red. The 
methionine (underlined and highlighted in blue), signifies the start/amino terminal of VP6. 
The sequence was derived using CLC genomics workbench v3.6.1 software (CLC Bio USA, 
Cambridge, MA). 
 
VP6 
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Figure 2-2: pET-28a(+) vector map 
The image was adapted from pET-28a-c(+) Vectors technical specification sheet (Novagen, 
product: TB074), Merck. The restriction sites (Nde I and the BamH I sites) are located within 
the multiple cloning site (MCS) where the VP6 gene was inserted. “Ori” represents the origin 
of replication; “Kan” represents the kanamycin resistant gene. The plasmid has been 
engineered to have two histidine tags, one situated on the N-terminus and the other on the 
C-terminus.  
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2.3. Cell transformation and over-expression of VP6 
The recombinant plasmid [VP6-pET-28a(+)] was introduced into the competent E.coli 
(BL21 and KRX strain) cells in a process called transformation (Kruger & Stingl, 
2011). The competent cells were thawed on ice along with an aliquot of the plasmid 
containing the VP6 coding insert. Then, 2 µl of recombinant plasmid was added to a 
100 µl of KRX and BL21 (DE3) competent cell vial, the reaction mixture was then 
gently swirled before being incubated on ice for 30 min. 
The cells were then heat shocked at 42°C for 45 s, then quickly incubated back on 
ice for 2 min. Then SOC media, preheated at 42°C, was added to the mixture and, 
incubated for 60 min at 37°C, before the cells were plated on an LB-agar containing 
0.05 mg/ml of kanamycin. The agar-plates were incubated at 37°C for 20 h. A single 
colony from successfully transformed cells was added to a fresh 25 ml LB broth 
supplemented with 0.05 mg/ml kanamycin. The cells were grown at 37°C for 20 h, 
then added to a fresh LB broth that was supplemented with 0.05 mg/ml kanamycin 
with a dilution of 1:50. The cells were grown at 37°C until the OD600 reached an 
absorbance of approximately 0.6. 
 
To test for the most optimum conditions for expressing soluble VP6, two E.coli cell 
strains (BL21 and KRX) were induced with different IPTG concentrations (0.0001 M; 
0.0005 M and 0.001 M). The KRX cells were also induced with either 0.05% or 0.1% 
(w/v) of L-rhamnose. The IPTG functions as allolactose by binding to the lac 
repressor, changing its structure and preventing it from binding to the promoter 
region, and allowing the highly selective RNA polymerase to transcribe the T7 
promoter (Studier & Moffat, 1986; Narita & Tokuda, 2009). 
KRX cells have a copy of T7 RNA polymerase gene driven by a rhamnose promoter 
whose expression is induced by L-rhamnose (Hartnett et al. 2006), thus all 
expression trials with KRX cells were tested with the addition of L-rhamnose for 
induction. The IPTG and L-rhamnose concentrations used in this study were 
selected on basis of suitable inducer concentrations for expressing soluble proteins 
from the technical bulletin, Single Step (KRX) Competent Cells instruction manual 
(www.promega.com/protocols). 
Two separate flasks were used when performing experiments for time-dependant 
experiments of 6 h and 16 h analysis, and when performing temperature dependent 
experiments of 25°C or 37°C. 
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After expression the cells were harvested via centrifugation at 5000 rpm, at 4°C for 
20 min, the cells where then resuspended in one of the different buffers (the specific 
buffers are mentioned in the results text). The resuspended cells were then 
sonicated on ice for 90 s at amplitude 35 using an ultrasonic liquid processor Q700 
(QSonica, 53 Church Hill Rd. Newtown, CT, USA). The sonicated cells were then 
centrifuged at 13 000 rpm, at 4°C for 20 min. Samples of the supernatant and pellet 
(re-solubilised first) were then electrophoresed through a 12% SDS-PAGE gel. 
 
2.4. SDS-PAGE 
The expressed proteins and the post-purification fractions were assessed by SDS-
PAGE with a discontinuous buffer system, prepared as described by Laemli, (1970). 
The resolving gel was a 12% acrylamide/bis-acrylamide gel [0.38 M Tris/HCl, pH 8.8, 
0.1% (w/v) SDS, 0.02% (w/v) ammonium persulphate and 0.09% (v/v) TEMED], and 
the stacking gel consisted of 4% polyacrylamide [0.13 Tris/HCl, pH 6.8, 0.1% (w/v) 
SDS, 0.06% (w/v) APS and 0.25% (v/v) TEMED]. Before the protein samples were 
loaded onto the gel wells they were mixed at a ratio of 1:1 with a sample buffer 
[0.0625 M Tris-HCl buffer, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) β-
mercaptoethanol and 0.05% (v/v) bromophenol blue], and then boiled for 5 min. The 
samples were loaded and electrophoresed for an hour at 160 Volts using a Bio-Rad 
Mini-PROTEAN Tetra cell. The electrode buffer contained 0.3% (w/v) Tris/HCL, 
1.88% (w/v) glycine and 0.1% (w/v) SDS. The unstained molecular weight marker 
was from Thermo Fisher Scientific (Massachusetts, USA) contained a mixture of 
proteins sizes ranging from 14 kDa to 116 kDa. Equal volumes (10 µl) of protein 
samples of were loaded onto the gel. After electrophoresis the gels were stained in 
0.2% (w/v) Coomassie Blue R250 dissolved in 10% (v/v) acetic acid, and 18% (v/v) 
methanol, and destained in a 10% (v/v) ethanol and 7% (v/v) acetic acid solution. 
Protein samples containing VP6 were electrophoresed against a molecular weight 
marker with the 45 kDa marker used as a qualitative measure for the presence of 
VP6, this is because the VP6 has a theorectical size of 46.58 kDa when expressed 
with 12 histidine residues.  
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2.5. Ammonium sulphate protein precipitation. 
Ammonium sulphate (AS) precipitation is an ideal technique used in the preparation 
of proteins prior to purification (Polson et al. 2003 Jiang et al. 2004). The soluble 
protein fractions were aspirated and aliquoted into four tubes that contained different 
AS percentage saturation of 10 (900 µl of protein and 100 µl of AS); 12% (880 µl of 
protein and 120 µl of AS); 16% (840 µl of protein and 160 µl of AS) and 20% (800 µl 
of protein and 200 µl of AS). The four tubes were mixed gently, incubated for 20 min, 
and then centrifuged at 13 000 rpm. Supernatants from the four tubes were removed 
to four different tubes and the precipitated proteins were re-solubilised in 500 µl of 
Buffer B. Both the supernatants and the re-solubilised pelleted fractions were 
electrophoresed on an SDS-PAGE gel. 
 
2.6. Protein purification 
The purification techniques used in the current study were ion anion exchange 
chromatography and affinity chromatography, performed on a Bio-Rad NGC 
Chromatography System. 
 
2.6.1. HisTag affinity chromatography 
Affinity chromatography is based on purifying biomolecules from one another based 
on the fact that they possess inherent recognition sites that can bind to a natural or 
artificial molecule bound to a fixed column. In the current study the affinity 
chromatography used was a HisTag affinity chromatography. 
The HisTag has an affinity for metal ions (i.e. nickel) to which it selectively binds 
during purification, this occurs because of the electron donor groups on the histidine 
imidazole ring that form bonds with metal (Ni2+) (Bornhorst & Falke, 2000) 
The supernatant obtained from cell lysate after centrifugation was applied to a 
HisTrap column (the volume of the columns used is stated in the results text) that 
was equilibrated with Buffer A. The column was washed with 4   column volumes 
(CV) of Buffer A, followed by a 10   CV linear elution gradient of mixing Buffer A with 
the same buffer containing a higher imidazole concentration (specific imidazole 
concentrations are stated in the results text), the fractions were collected in volumes 
of 4 ml. 
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2.6.2. Ion exchange chromatography 
Ion exchange chromatography is based on attraction between a charged fixed 
column matrix that is commonly made up of polysaccharides such as Sepharose 
containing a charged species (Jungbauer & Hahn, 2009). In the case of protein 
purification using ion exchange chromatography the protein’s charge is affected by 
its the buffer pH. The buffer pH manipulates the charge of the protein considering the 
proteins pI, if the protein is in a buffer with a pH below its pI the protein is protonated 
and becomes positively charged, if the buffer pH is above the protein’s pI then 
deprotonation occurs giving the protein a net negative charge. Positively charged 
proteins bind to negatively charged Sepharose beads, and vice versa. 
Protein supernatant were obtained as described in section 2.3 above, the cells were 
resuspended in Buffer B before lysis. The resuspended cells were lysed then 
centrifuged for 20 min as described in section 2.3 above. The supernatant was 
loaded on a 35 ml DEAE column that was pre-equilibrated and washed with Buffer B. 
A 10   CV elution gradient of Buffer B against Buffer B containing a higher sodium 
chloride concentration (specific sodium chloride concentrations are stated in the 
results text) was used for elution. In ion exchange chromatography the fractions 
were collected in volumes of 8 ml 
 
2.7 Absorbance spectroscopy 
Absorbance of VP6 was measured from 340 nm to 220 nm, before the corrected 
absorbance at 280 nm was used to determine the protein concentration using a 
Chirascan plus instrument (PhotoPhysics, Leatherhead, UK). The Beer-Lambert Law 
(A = c.ɛ.l) was used to calculate the protein concentration from the corrected 
absorbance (A340 subtracted from A280) reading, where A is the absorbance 
determined, ɛ is the extinction coefficient, which is a constant, “c” is the 
concentration of the solution containing absorbing molecule, and “l” is the cuvette 
path length which was 1 cm unless otherwise specified. Before every absorbance 
reading a background correction was performed using the buffer in which the protein 
was suspended. Absorbance was read at 1 nm step and performed in triplicates, 
then produced an average spectrum. The extinction coefficient of RV VP6 was 
calculated to be 42 525 M-1.cm-1 using ExPASy ProtParam tool (Gasteiger et al. 
2005). Protein concentration obtained after purification varied in some 
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characterisation experiments, concentration for each experiment is stated in the 
results text. 
 
2.8. Fluorescence 
Fluorescence spectrophotometry is the emission of light from a molecule that has 
been excited to a higher electronic state after it has absorbed light. Light absorbance 
by a molecule is specific to a particular wavelength of light based on the molecule’s 
electron properties. The excited molecule only has a short excited state or lifetime, it 
will then return to ground state and emit light. The light emitted usually has a lower 
energy and a longer wavelength compared to the light absorbed by the molecule 
(Ward et al. 1991). 
Phenylalanine, tyrosine and tryptophan contain 5 or 6 membered aromatic rings and 
are intrinsic fluorophores in proteins. Tyrosine and tryptophan are excited by 
wavelengths of 280 nm and 295 nm, respectively. 
In the current study intrinsic fluorescence was used to identify the local tertiary 
environment around the fluorophores of VP6 when excited at 280 nm and 295 nm. A 
background correction was performed before any fluorescence reading was carried 
out using an empty 10 mm pathlength quartz cuvette that was used to hold the 
protein sample. Fluorescence emission spectra were recorded in the range of 500 
nm to 280 nm at 20°C in triplicates which were used to produce an average 
spectrum. Excitation and emission slit widths were both set at 5 nm. A pathlength of 
1 cm was used for all intrinsic fluorescence experiments. 
 
2.9 Circular dichroism 
Circular dichroism (CD) refers to the differential absorption of left and right circularly 
polarized light (Atkins & de Paula, 2005). A circular dichroism spectrum is influenced 
by the aromatic amino acid residues; the twists of the β sheets, and the lengths of 
the α-helices (Johnson, 1999), making it ideal for assessing the secondary structure 
of a protein. Far UV CD uses a range of wavelengths from 250 nm to 190 nm for 
peptide bond absorbance in determining the secondary structural content of a 
protein. A background correction was performed before any far-UV CD reading was 
carried out using an empty quartz cuvette that was used to hold the protein sample. 
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Far-UV CD spectra ranged were recorded at 20°C in triplicates which were used to 
produce an average spectrum. A 1 mm path length quartz cuvette was used during 
far-UV CD with the bandwidth set to 1 nm. 
 
2.10. Thermal unfolding. 
Thermal unfolding was measured by exposing VP6 to increasing temperatures from 
20°C to 90°C. Heat denaturation of VP6’s secondary structure was assessed by 
monitoring the far-UV CD using specifications stated in section 2.9. Ellipticity was 
measured at 1 nm step per temperature increase using 0.5 nm bandwidth. 
Heat denaturation of VP6’s tertiary structure was assessed by monitoring 
fluorescence emission at 1 nm step per temperature increase. 
 
All protein characterisation experiments were performed using a Chirascan Plus 
instrument (PhotoPhysics, Leatherhead, UK). 
 
2.11. Software and equations used for structural analysis, sequence analysis 
and data fitting 
2.11.1. Calibration curve 
The molecular weight of VP6 was analysed according to the migration distance on 
SDS-PAGE gel with reference to the molecular weight standards. The size of VP6 
was extrapolated from a calibration curve constructed using the size and migration of 
the molecular weight standards. The size of the protein standards were represented 
as log values. An example of a calibration curve represented in the results section is 
shown in Appendix A. 
 
2.11.2 Mean residue ellipticity 
The circular dichroism ellipticity values (except for those used to monitor thermal 
unfolding experiment) were represented as mean residue ellipticity [θ] calculated 
from equation:  
[θ] = 100 (θ or mdeg )/ (c   n   l). 
Where “c” is the molar concentration of the protein in mM, “n” is the number of amino 
acid residues in the polypeptide chain and “l” is the pathlength in cm. 
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2.11.3 Software 
Protein illustrations were generated through PyMol version 1.7 [Delano Scientific, 
(2009)]. 
Images and life cycles were generated using Microsoft Office PowerPoint (2010). 
VP6 protein sequence was obtained from CLC genomics workbench version 3.6.1 
software (CLC Bio USA, Cambridge, MA).  
Linear and non-linear graphs were fitted using Microsoft Office Excel (2010). 
Absorbance, circular dichroism and fluorescence data was acquired using Chirascan 
version 4.4.0 software.  
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Chapter 3: Results 
 
3.1. Protein over-expression 
The recombinant pET-28a(+) plasmid with the RV VP6 gene insert was used to 
transform E.coli (BL21 and KRX strain) cells. Expression trials were performed to 
determine the optimum conditions for over-expressing soluble rotavirus VP6 in both 
lines. The expression conditions that were tested include: inducer concentration 
(IPTG in both cell lines and L-rhamnose in the KRX cells); post-induction growth 
temperature and post-induction growth time. 
 
3.1.1. Optimizing inducer concentration 
Total over-expression of VP6 inside both cell lines was tested, with the cells exposed 
to varying inducer concentrations described in section 2.3, and incubated at a post-
induction temperature of 25°C for 6 h. The cell cultures were harvested and then 
sonicated using the methods explained in section 2.3. 
 
3.1.1.1. KRX cells 
The IPTG concentration was used at 0.0001 M and 0.0005 M with no observable 
difference in expression of VP6 when comparing proteins present in the whole cell 
lysates, but it was observed that no VP6 was expressed when L-rhamnose was 
omitted from the bacterial growth culture (Figure 3-1). 
The whole cell lysates were centrifuged to separate the soluble proteins from 
insoluble proteins. It was observed that KRX cells expressed more soluble VP6 (see 
supernatant content in Figure 3-2), than the BL21 cells (see supernatant content in 
Figure 3-3). The KRX cells also showed no variation in over-expression of VP6 when 
induced with either 0.05% or 0.1% L-rhamnose with any combination of IPTG 
concentration of either 0 M or 0.0005 M IPTG.  
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Figure 3-1: Optimisation of inducer concentration observed in whole cell lysates of BL21 and KRX cells 
The effect of IPTG and L-rhamnose which represented by “rham” in were used to over-express VP6 in E.coli BL21 (DE3) and KRX cells. The 
SDS-PAGE lanes are labelled by the inducer concentration used. All cells with their respective IPTG and L-rhamnose concentrations were 
grown at 25°C for 6 h after induction. Molecular weight marker represented as “MWM” is represented in kDa. The 45 kDa mark is used to mark 
migration of VP6 that has a molecular weight of 50.12 kDa as determined using a calibration curve and data from this gel image (example of 
the calibration curve is depicted in Appendix A). 
kDa 
VP6 
kDa 
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Figure 3-2: Effect of IPTG and L-rhamnose concentrations on expression of soluble versus insoluble VP6 in KRX cells 
IPTG concentrations of 0; 0.0001; or 0.0005 M were assessed along with L-rhamnose represented by “rham” concentrations of 0; 0.05 or 0.1% 
(w/v). “S” represents the soluble proteins obtained from the supernatant and “P” represents the pelleted proteins precipitated the re-solubilised 
from the cell lysate. “MWM” represents the molecular weight marker in kDa. The 45 kDa marker is used to mark migration of VP6 which has a 
molecular weight of 50.12 kDa as determined using a calibration curve and data from this SDS-PAGE gel (example of a calibration curve is 
depicted in Appendix A). 
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Figure 3-3: Effect of IPTG concentration on expression of VP6 in BL21 cells 
IPTG concentrations of “0 M”; “0.0001 M”; “0.0005 M” and “0.001 M” are shown on the SDS-
PAGE gel lanes. “S” represents the soluble proteins obtained from the supernatant and “P” 
represents the pelleted proteins precipitated then re-solubilized from the cell lysate. “MWM” 
represents the molecular weight marker in kDa. The 45 kDa marker is used to mark 
migration of VP6 which has a molecular weight of 52.48 kDa as determined using a 
calibration curve and data from this SDS-PAGE gel (example of the calibration curve is 
depicted in Appendix A) 
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The high molecular weight of VP6 was due to the presence of the added 12 histidine 
residues along with extra amino acids from the plasmid. There was no expression of 
VP6 in KRX cells when L-rhamnose was omitted from the cells culture during 
induction with IPTG. This shows the crucial role of L-rhamnose in protein over-
expression using KRX cells. 
 
3.1.1.2. BL21 cells 
Over-expression of VP6 was observed to be equal in BL21 (DE3) cells compared to 
the KRX cells when induced with either 0.0001 M or 0.0005 M IPTG (Figure 3-1), but 
separation of supernatant from pelleted proteins in BL21 cells showed that more of 
the VP6 was expressed as insoluble aggregates (present in the “P” lanes, Figure 3-
3). There was no change in the amount of expressed VP6 in BL21 cells when IPTG 
concentration was increased (Figure 3-3). 
 
3.1.2 Optimisation of post-induction incubation temperature 
Protein expression is dependant not only on inducer concentration but also on the 
growth temperature. This determines the rate of cell growth and the protein over-
expression. Post-induction temperatures of 25°C and 37°C were tested on their 
effect on over-expression of soluble VP6 in BL21 and the KRX cells. The induction 
time was kept constant at 6 h along with an IPTG concentration of 0.001 M for BL21 
cells, and 0.0005 M and 0.1% (w/v) L-rhamnose for KRX cells. 
 
3.1.2.1. BL21 cells 
Expressing VP6 in BL21 cells at 37°C (Figure 3-4), produced a higher yield of VP6, 
but most of the protein was located in the pellet fractions and is, hence, insoluble. 
VP6 expressed at 25°C was expressed equally in both the supernatant and the 
pellet. This was because bacteria grow optimally at temperatures of ±37°C. High 
expression levels of recombinant protein often result in its aggregation and 
accumulation in inclusion bodies (Lilie et al. 1998). Decreasing bacterial culture 
temperature reduces the growth rate of cells and the expression of proteins, and this 
also reduces the rate at which proteins aggregate and form inclusion bodies 
(Georgiou & Valax, 1996).  
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3.1.2.2. KRX cells 
KRX cells were grown at 37°C, induced at a reduced temperature of 25°C. But the 
cell culture that was used for expression of VP6 at 37°C was maintained at that 
temperature even after induction. 
There were no differences in the expressed soluble VP6 from the KRX cells 
incubated at 25°C and those incubated at 37°C (Figure 3-5), indicating that variation 
in the induction temperature had no effect on expression of soluble VP6 in KRX 
cells. 
The ideal post-induction temperature for expressing soluble VP6 chosen for the 
study was 25°C, as the use of low post-induction temperature for bacterial 
expression systems was recommended by Xue et al. (2015). 
 
3.1.3 Assessment of optimum induction growth time for protein over-
expression 
The induction duration was tested to establish any difference in amount of expressed 
soluble VP6 over induction time of 6 h versus 16 h and above. Inducing for a longer 
period of time (i.e. 16 h) may help increase the number of cells in the growth culture 
and, hence, the amount of protein. However, inducing for a longer period of time 
implies that there will be a gradual increase in the presence of dead cells, which in 
turn release proteases (Chakrabarti et al. 2016). Both the 6 h and the 16 h post-
induction trial was tested to observe the most appropriate induction required for 
expressing high amounts of soluble VP6. 
 
3.1.3.1. BL21 cells 
There was no difference in the amount of soluble VP6 from both the 6 h and the 16 h 
induction growth times (Figure 3-6), meaning either induction time may be used to 
express soluble VP6 in BL21 cells. 
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Figure 3-4: Effect of post-induction temperature on over-expression VP6 in BL21 cells 
Temperatures of “37°C” and “25°C” were used to incubate the induced BL21 cells. “S” 
represents the soluble proteins obtained from the supernatant and “P” represents the 
pelleted proteins precipitated from the cell lysate. The cells were induced with 0.001 M IPTG 
for 6 h. “MWM” represents the molecular weight marker in kDa. The 45 kDa marker was 
used to mark the migration of VP6 which has a molecular weight of 48.98 kDa as determined 
using a calibration curve constructed from this SDS-PAGE gel (an example of a calibration 
curve is depicted in Appendix A). 
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Figure 3-5: Effect of post-induction temperature on over-expression of VP6 in KRX 
cells 
Temperatures of “37°C” and “25°C” were used to incubate induced KRX cells. “S” represents 
the soluble proteins obtained from the supernatant and “P” represents the pelleted proteins 
precipitated from the cell lysate. The cells were induced with 0.0005 M IPTG and 0.1% (w/v) 
L-rhamnose for 6 h. “MWM” represents the molecular weight marker in kDa. The 45 kDa 
marker was used to mark migration of VP6 which has a molecular weight of 52.48 kDa as 
determined using a calibration curve and data from this SDS-PAGE gel (example of a 
calibration curve is depicted in Appendix A). 
  
VP6 
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Figure 3-6: Effect of induction growth time on over-expression of VP6 in BL21 cells 
Induction growth times of “16 h” and “6 h” were used in the expression of VP6 in induced 
BL21 cells. “S” represents the soluble proteins obtained from the supernatant and “P” 
represents the pelleted proteins precipitated from the cell lysate. The cells were induced with 
0.001 M IPTG and incubated at 25°C after induction. “MWM” represents the molecular 
weight marker in kDa. The 45 kDa marker is used to mark migration of VP6 which has a 
molecular weight of 50.12 kDa as determined using a calibration curve and data from this 
SDS-PAGE gel (example of the calibration curve is depicted in Appendix A). 
  
VP6; 44.9 kDa 
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3.1.3.2. KRX cells 
The 16 h induction time for KRX expression shows that there was a greater yield of 
proteins indicated by the dark bands on the SDS-PAGE from both the supernatant 
and pellet lanes (Figure 3-7); this was a result from a higher cell growth in the 
culture. 
A 6 h induction time was preferred for this study because the lower the induction 
growth time the lower the cell death, hence less proteases present (Chakrabarti et al. 
2016). The conditions used for BL21 cell growth and VP6 over-expression also 
resulted in increased expression of a protein species other than VP6 (Figures 3-3, 3-
4 and 3-6), this protein had a theoretical molecular weight of 41 kDa (determined 
using a calibration curve). The 41 kDa protein was also over-expressed in the KRX 
cells, but it was consistently found in the pellet fraction (Figure 3-2 and 3-5). 
BL21 cells yielded more VP6 overall, but the difference was observed in the yield of 
soluble VP6 which was higher in KRX cells. The KRX cells also produce less of the 
41 kDa protein in the supernatant, this simplifies purification. 
IPTG concentrations of 0.0001 M and 0.0005 M; L-rhamnose concentrations of 
0.05% and 0.1%; induction temperatures of 25°C and 37°C, and induction time of 6 h 
and 16 h did not have an impact on the expression of soluble VP6 in KRX cells. The 
conditions that were preferred for the current study are an IPTG concentration of 
0.0001 M; an L-rhamnose concentration of 0.05%, a post-induction temperature of 
25°C, and an induction time of 6 h were. These conditions were chosen because 
they are cost effective and are less time-consuming.  
 
3.2. Protein purification 
Over-expressed VP6 was purified using different liquid chromatography purification 
techniques, namely ion (cation and anion) exchange chromatography, and affinity 
chromatography.  
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Figure 3-7: Effect of induction growth time on over-expression of VP6 in KRX cells 
Induction growth times of “16 h” and “6 h” were used in the expression of VP6 in induced 
KRX cells. “S” represents the soluble proteins obtained from the supernatant and “P” 
represents the pelleted proteins precipitated from the cell lysate. The cells were induced with 
0.0005 M IPTG, 0.1% (w/v) L-rhamnose and incubated at 25°C after induction. “MWM” 
represents the molecular weight marker in kDa. The 45 kDa marker is used to mark 
migration of VP6 which has a molecular weight of 47.86 kDa as determined using a 
calibration curve and data from this SDS-PAGE gel (example of a calibration curve is 
depicted in Appendix A). 
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3.2.1 Nickel affinity (HisTag) chromatography 
VP6 was expressed using optimised conditions from section 3.1, then resuspended 
in Buffer A using procedure explained in section 2.3. The protein supernatant was 
collected and loaded on a 5 ml HisTrap resin from GE Healthcare (Little Chalfont, 
United Kingdom) that was equilibrated with Buffer A. The column was then washed 
with Buffer A, and eluted off the column using an elution gradient of Buffer A against 
Buffer A containing 0.3 M imidazole. The SDS-PAGE shows that VP6 did not bind to 
the HisTrap resin under these conditions and was completely washed off the column 
during a wash with Buffer A (Figure 3-8). 
Bugli et al. (2014) used small ubiquitin-like modifier (SUMO) along with HisTag on 
VP6 to increase solubility of the target protein. Badillo-Godinez et al. (2015) added 8 
M urea to the whole cell lysate in order to produce soluble proteins that can bind the 
nickel resin. The presence of a denaturant helps unfold the protein, thus, exposing 
the HisTag expressed with the protein, allowing it to bind to the nickel Sepharose 
resin. 
An affinity chromatography using HisTrap resin was performed with the addition of 6 
M urea to Buffer A was performed. An elution gradient spanning 0.01 M to 0.3 M 
imidazole was used to elute VP6 off the column. VP6 was successfully bound to the 
column and was eluted in collected fractions (Figure 3-9). VP6 was also present in 
the wash fraction, but that could have been a result of having exceeded the binding 
capacity of the resin. 
VP6 was eluted approximately at 31% of the elution gradient; and was still not 
completely purified of other cellular proteins. Studies from Oldfield et al. (1990) and 
Li et al. (2014) described the use of ammonium sulphate precipitation to precipitate-
out the protein of interest, thus reducing the amount of cellular proteins that compete 
with the target protein for binding on the column. 
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Figure 3-8: Affinity (HisTag) chromatography purification of VP6 using a sodium 
phosphate buffer and a gradient elution of 0.01 M to 0.3 M imidazole 
A. The elution chromatographic profile illustrating the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicating the lane 
for the “MWM” which represents the molecular weight marker in kDa. The lane marked “S” 
represents the soluble proteins obtained from the supernatant of the cell lysate loaded on 
the column. “P” represents the pelleted proteins precipitated from the cell lysate. The lane 
labelled “FT” represents the flow-through protein sample that did not bind, but passed 
through the column during sample loading. The lane marked “Wash” represents the proteins 
from the column wash, where loading buffer was allowed to pass through the column to 
remove any unbound proteins. Lanes marked with “A/2” to “A/6” are protein fractions that 
were collected during the elution gradient from 0.01 M up to 0.3 M imidazole concentration.  
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A. 
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Figure 3-9: Affinity (HisTag) chromatography purification of VP6 using a sodium 
phosphate buffer, 6 M urea, and a gradient elution of up to 0.3 M imidazole 
A. The elution chromatographic profile illustrating the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicating the lane 
for the “MWM” which represents the molecular weight marker in kDa. The lane marked “S” 
represents the soluble proteins obtained from the supernatant of the cell lysate loaded onto 
the column. “P” represents the pelleted proteins precipitated from the cell lysate. The lane 
labelled “FT” represents the flow-through protein sample that did not bind, but passed 
through the column during sample loading. The lane marked “Wash” represents the proteins 
from the column wash fraction, where loading buffer was allowed to pass through the column 
to remove any unbound proteins. Lanes marked with “A/16”; “A/18” and “A/19” are protein 
fractions that were collected during the elution gradient set from 0.01 M up to 0.3 M 
imidazole concentration. 
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3.2.2 Salting out 
Ammonium sulphate is widely used as a preparative method to concentrate and 
selectively separate target proteins from other protein species. Protein samples are 
pre-treated before purification in order to help purification reach a higher purity level 
after performing purification (Mini et al. 2016). Oldfield et al. (1990) made use of 20% 
AS to precipitate bluetongue VP7 which is a structurally similar protein to RV VP6. 
VP7 was dialysed against a 0.01 M Tris-HCl buffer, at pH 7.5, and then loaded the 
protein onto a DEAE Sephacel column. The proteins were successfully precipitated 
in large yields and excluded most of the other host cellular proteins (Oldfield et al. 
1990). 
To carry out the salting-out procedure VP6 was expressed in KRX cells, and 
supernatant was obtained procedures stated in section 2.3. The supernatant was 
treated as described in section 2.5. it was found that precipitation using AS was non-
selective, and failed to separate VP6 from other bacterial cellular proteins (Figure 3-
10), and increasing the AS concentration would only precipitate the other bacterial 
protein species along with VP6.  
Salting-out proteins can affect results on proteomic studies these include affecting 
their interaction and modification, influencing behaviour during purification and 
conformation during structural characterisation (Fountoulakis, 2001). Jiang et al. 
(2004) also reported that target proteins are not completely recovered after salting 
out. 
 
3.2.3 Anion exchange chromatography 
Vicente et al. (2008) used a weak anion exchange matrix (i.e. DEAE), and also 
reported that this purification procedure was essential in purifying RV proteins as it 
requires a nearly neutral pH (pH 7.4) which is less aggressive when considering 
developing a vaccine and important in preserving the stability of the protein.  
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Figure 3-10: Protein precipitation using ammonium sulphate. 
AS represents the ammonium sulphate used in different concentrations to precipitate the 
protein sample. “S0” presents the initial supernatant with no AS. “S” represents the 
supernatant obtained from addition of AS followed by centrifugation; and “P” represents the 
precipitated proteins collected from the pelleted protein sample after the addition of AS and 
centrifugation. The protein sample aliquots were exposed to different AS concentrations from 
0% up to 20%. “MWM” represents the molecular weight marker in kDa. The 45 kDa marker 
is used to mark migration of VP6.  
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Purification of VP6 was performed on a DEAE resin, the column was equilibrated 
and washed with Buffer C. An elution gradient was from 0 M to 0.3 M sodium 
chloride was used to elute VP6 off the column. Most of the VP6 failed to bind to the 
resin (Figure 3-11), while the small amounts of the protein that did bind were found 
to be present at different elution gradient percentages. This indicates that VP6 was 
present in different conformation, thus, displaying instability. 
 
Sodium phosphate is the most commonly used buffer in anion exchange purifications 
(Choi et al. 1999). Buffer B was used to resuspend the pelleted cells before 
sonication and centrifugation. The supernatant was loaded on a DEAE column pre-
washed with Buffer B. The bound proteins were eluted off the column using an 
elution gradient between Buffer B against a 1 M sodium chloride Buffer B. VP6 was 
successfully bonded to the DEAE resin, and absence of VP6 in the column wash 
fraction indicated that it was bound to the column (Figure 3-12). VP6 was eluted 
early in the gradient, and it was not isolated from other cellular proteins. 
 
 The protein sample was suspended in Buffer B before being loaded onto a DEAE 
column that was pre-equilibrated with Buffer B. The column was washed and an 
elution gradient between Buffer B against Buffer containing 0.7 M sodium chloride 
was used. The gradient length was shortened to better isolate VP6 from other 
cellular proteins. Fractions were collected as the absorbance started to increase by 
two units (Figure 3-13 A.). There were no presence of VP6 in the regeneration 
fraction indicating that an elution gradient of up to 0.7 M sodium chloride was 
sufficient in eluting VP6 off the column. A reduction in the elution gradient from 1 M 
to 0.7 M helped separate the eluted VP6 from many of the cellular proteins, and 
elution of VP6 at an early stage in the elution gradient indicates that the elution 
gradient could be further reduced to increase the purity of VP6. 
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A. 
 
B. 
Figure 3-11: Anion (DEAE Sepharose) exchange chromatography purification of VP6 using a MOPS buffer with a gradient elution of 
up to 0.3 M sodium chloride 
A. The elution chromatographic profile illustrated the absorbance at 280 nm (blue line), conductivity (red line) and elution gradient (green line). 
B. SDS-PAGE gel indicates the lane for the “MWM” which represents the molecular weight marker in kDa. The lane marked “S” represents the 
soluble proteins obtained from the supernatant of the cell lysate loaded onto the column. “P” represents the pelleted proteins precipitated from 
the cell lysate. The lane labelled “FT” represents the flow-through protein sample that passed through the column during sample loading. The 
lane marked “Wash” represents the proteins washed from column during the wash step. Selected fractions between “A/15” to “A/60”, and “B/2” 
represent fractions that were collected during the elution gradient from 0 M up to 0.3 M sodium chloride. 
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Figure 3-12: Anion (DEAE Sepharose) exchange chromatography purification of VP6 
using a sodium phosphate buffer and a gradient elution of up to 1 M sodium chloride. 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicates the 
“MWM” lane which represents the molecular weight marker in kDa. The lane marked “S” 
represents the soluble proteins obtained from the supernatant of the cell lysate loaded on 
the column. “P” represents the pelleted proteins precipitated from the cell lysate. The lane 
labelled “FT” represents the flow-through protein sample that did not bind, but passed 
through the column during sample loading. The lane marked “Wash” represents the proteins 
washed from column during the wash step. Selected fractions between “A/35” to “A/60” 
represent fractions that were collected during the elution gradient from 0 M up to 1 M sodium 
chloride. 
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Figure 3-13: Anion (DEAE Sepharose) exchange chromatography purification of VP6 
using a sodium phosphate buffer and a gradient elution of up to 0.7 M sodium 
chloride 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicating the lane 
“MWM” represents the molecular weight marker in kDa. The lane marked “S” represents the 
soluble proteins obtained from the supernatant of the cell lysate loaded on the column. “P” 
represents the pelleted proteins precipitated from the cell lysate. Selected fractions between 
“A/4” to “A/60” and “B/11” represent fractions that were collected during the elution gradient 
from 0.08 M up to 0.7 M sodium chloride.  
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Proteins can be eluted by changes in pH or sodium chloride on ion-exchange resins. 
Theoretically, a pH lower than VP6’s pI (6.65) would render a net positive charge, 
causing the like-charged molecules (VP6 and the Sepharose beads) to repeal each 
other. After protein loading and column wash procedures using Buffer B, the proteins 
were eluted using an elution gradient between Buffer B against Buffer B, pH 5.0, and 
0.1 M sodium chloride. At the end of the gradient VP6 was not eluted off the column 
and was only eluted after 1 M sodium chloride buffer was exposed to the column 
(Figure 3-14 A and B.). The combination of a low pH and a low sodium chloride 
concentration was not able to eluting VP6 off the DEAE column. 
 
More protein was expressed in KRX cells, suspended in Buffer B, and was applied to 
the DEAE Sepharose column, which was then washed with the same buffer before 
loading 2   CV of Buffer B at pH 6, followed by 2   CV of Buffer B at pH 5.5, then 
another 2   CV of Buffer B at pH 5. This was done to determine the pH which can be 
used to elute VP6 off a DEAE column. The column was then regenerated with 1 M 
sodium chloride buffer. None of the buffers at pHs of 6; 5.5 or 5.0 were able to elute 
VP6 (Figure 3-15); nor did they elute other bacterial cellular proteins to further purify 
VP6. VP6 was present in fractions A/3 to A/5 (Figure 3-15 B). The experiment 
confirmed that VP6 was not eluted off the DEAE column by reducing the pH 
environment of the protein. The theoretical pI of the protein is based solely on the 
amino acid sequence, and the pH could have induced changes that only altered the 
tertiary or quaternary structure of the protein, resulting in the behaviour in question. It 
was found that an elution gradient of up to 0.7 M of sodium chloride can elute VP6 
off a DEAE column when purifying with a sodium phosphate buffer at pH 7.04 
(Figure 3-13). The lowest sodium chloride concentration required for eluting VP6 has 
not been established, which is essential for creating better separation of eluted 
proteins, thus increasing the purity of VP6. 
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B. 
Figure 3-14: Anion (DEAE Sepharose) exchange chromatography purification of VP6 using a sodium phosphate buffer and a gradient 
elution of up to 0.1 M sodium chloride at pH 5.0. 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), conductivity (red line) and elution gradient (green line). 
B. SDS-PAGE gel indicates the lane “MWM” which represents the molecular weight marker in kDa. The lane marked “S” represents the soluble 
proteins obtained from the supernatant of the cell lysate loaded onto the column. “P” represents the pelleted proteins precipitated from the cell 
lysate. The lane labelled “FT” represents the flow-through protein sample that did not bind, but passed through the column during sample 
loading. The lane marked “Wash” represents the proteins washed from column during the wash step. Selected fractions between “A/1” and 
“A/3” represent fractions that were collected during the elution gradient from 0.08 M up to 0.1 M sodium chloride at pH 5.0. Fractions labelled 
“A/4” to “A/14” represent fractions that were collected during column regeneration with a 1 M sodium chloride buffer.  
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A. 
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Figure 3-15: Anion (DEAE Sepharose) exchange chromatography purification of VP6 
using a sodium phosphate buffer and varying pH for elution 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and the percentage of 0.05 M sodium phosphate buffer, pH 7.04, 
containing 0.08 M sodium chloride is represented as a green line. Buffers used were 0.05 M 
sodium phosphate buffers prepared at pH 6.0; 5.5; and at 5.0. B. SDS-PAGE gel indicating 
the lane “MWM” represents the molecular weight marker in kDa. The lane marked “S” 
represents the soluble proteins obtained from the supernatant of the cell lysate loaded onto 
the column. The lane labelled “FT” represents the flow-through protein sample that did not 
bind, but passed through the column during sample loading. The lane marked “Wash” 
represents the proteins washed from column during the wash step, with Buffer B at pH 7.04. 
Lanes marked “pH 6.0”; “pH 5.5”; and “pH 5.0” were proteins fractions collected during their 
respective pH buffer. Selected fractions between “A/2” and “A/7” represent fractions that 
were collected during column regeneration with 1 M sodium chloride.  
A280  
100 % Buffer B 
Conductivity 
0 % Buffer B 
48 
 
To determine a better sodium chloride concentration required to isolate VP6 required 
an experiment that involves washing the column containing VP6 with increasing 
sodium chloride concentrations of Buffer B. The selected sodium chloride buffers are 
0.2 M, 0.3 M, 0.5 M and 0.7 M. The first elution wash was with 0.2 M sodium 
chloride; followed by a 0.3 M sodium chloride; then a 0.5 M sodium chloride, and 
lastly a 0.7 M sodium chloride buffer (Figure 3-16 A.). Each elution was performed 
using 2 x CV of the sodium chloride buffer. VP6 was eluted at 0.2 M, 0.3 M and 0.5 
M sodium chloride concentration but most of VP6 was eluted at the lowest sodium 
chloride concentration (Figure 3-16 B.). From the results it was deduced that an 
elution gradient of up to 0.2 M sodium chloride is essential to successfully eluting 
VP6 off a DEAE column and is low enough to create better separation between VP6 
and other cellular proteins. 
The modified conditions for purifying VP6 on a DEAE column using an elution 
gradient were tested with an elution gradient from 0.08 M up to 0.2 M sodium 
chloride. The supernatant containing VP6 was loaded to the column, and washed 
with 4   CV of Buffer B before the elution gradient was initiated. During elution 
fractions were collected and analysed on an SDS-PAGE gel (Figure 3-17 B.). VP6 
was eluted with the elution gradient of 0.08 M to 0.2 M sodium chloride. VP6 was 
present in fractions A/18 to A/24 (which was eluted by a sodium chloride 
concentration of approximately 0.15 M). 
Results obtained from purifying VP6 using DEAE column chromatography showed 
that most bacterial cellular proteins are separated from VP6. The absence of VP6 in 
the unbound protein sample and regeneration with 1 M sodium chloride after a 
gradient elution of up to 0.2 M sodium chloride concentration indicates that there is 
little loss of VP6 during the anion exchange chromatography purification (Figure 3-18 
B.). A second purification was still required as VP6 was not purified from other 
bacterial protein species. 
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Figure 3-16: Anion (DEAE Sepharose) exchange chromatography purification of VP6 
using a sodium phosphate buffer and sodium chloride elution using 0.2 M, 0.3 M, 0.5 
M and 0.7 M concentrations 
A. The elution chromatographic profile illustrates the absorbance at 280 nm read at different 
sodium chloride concentrations of 0 M; 0.2 M; 0.3 M; 0.5 M and 0.7 M. B. SDS-PAGE gel 
indicates the lane “MWM” which represents the molecular weight marker in kDa. The lane 
marked “S” represents the soluble proteins obtained from the supernatant of the cell lysate 
loaded onto the column. “P” represents the pelleted proteins precipitated from the cell lysate. 
Lanes marked “0 M”; “0.2 M”; “0.3 M”; “0.5 M”, and “0.7 M” represents protein fractions 
collected in their respective sodium chloride concentration. 
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Figure 3-17: Anion (DEAE Sepharose) exchange chromatography purification of VP6 using a sodium phosphate buffer and a gradient 
elution of up to 0.2 M sodium chloride 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), conductivity (red line) and elution gradient (green line). 
B. SDS-PAGE gel indicates the lane “MWM” which represents the molecular weight marker in kDa. The lane marked “S” represents the soluble 
proteins obtained from the supernatant of the cell lysate loaded onto the column. The lane labelled “FT” represents the flow-through protein 
sample that did not bind, but passed through the column during sample loading. The lane marked “Wash” represents the proteins washed from 
column during the wash step. “Regen” represents regeneration which signifies the protein collected during 1 M sodium chloride column wash. 
Selected fractions between “A/18” to “A/24” represent fractions that were collected during the elution gradient from 0.08 M up to 0.2 M sodium 
chloride. 
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Taraporewala et al. (2006) and Zhang et al. (2017) purified their target proteins using 
two different chromatography techniques to help achieve a higher level of purity by 
combining affinity and ion exchange chromatography. Seth et al. (2017) utilised three 
column chromatography purification techniques which included an initial purification 
using affinity chromatography (Ni2+ column), then an anion (Q Sepharose column) and 
then a cation (SP Sepharose column) exchange chromatography to further remove 
endotoxins, host cell proteins and residual DNA. 
 
3.2.4 Purification using affinity and ion exchange chromatography 
Seth et al. (2017); and Zhang et al. (2017) used affinity chromatography initially to 
partially purify their specific proteins of interest, followed by an ion exchange 
chromatography to complete the purification. 
In the current study an anion exchange chromatography was selected as an ideal 
technique to be used as a first step of partially purifying VP6, this was because the 
DEAE column had a high resin volume of 36 ml ensuring that the binding capacity is 
high. 
Supernatant containing VP6 was loaded onto the column, and then washed with 4   CV 
of Buffer B before a gradient elution from 0.08 M sodium chloride to 0.2 M sodium 
chloride. Fractions were collected during elution, and were analysed on an SDS-PAGE 
gel (Figure 3-18 B.). The fractions that were visualised to have VP6 were pooled, and a 
0.01 M imidazole was added along with 3 M urea to the pooled fractions. A lower 3 M 
urea was used in order to prevent complete unfolding of VP6 and other cellular proteins. 
Affinity chromatography was performed on a 5 ml HisTrap column which was 
equilibrated with Buffer A. 
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Figure 3-18: Partial purification of VP6 using anion (DEAE Sepharose) exchange 
chromatography with a gradient elution of up to 0.2 M sodium chloride 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicates the lane 
“MWM” which represents the molecular weight marker in kDa. The lane marked “S” represents 
the soluble proteins obtained from the supernatant of the cell lysate loaded on the column. The 
lane labelled “FT” represents the flow-through protein sample that did not bind, but passed 
through the column during sample loading. The lane marked “Wash” represents the proteins 
washed from column during the wash step. “Regen” represents regeneration which signifies the 
protein collected during 1 M sodium chloride column wash. Selected fractions between “A/18” to 
“A/24” represent fractions that were collected during the elution gradient from 0.08 M up to 0.2 
M sodium chloride.  
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The column was washed with Buffer A, and elution gradient used started from 0.01 M 
and ended with 0.2 M imidazole. 
The presence of VP6 in the fractions collected during the elution confirmed that there 
was VP6 that remained bound to the column during sample application (Figure 3-19 B).  
VP6 was not pure and, therefore, another HisTag affinity chromatography was 
conducted using fractions obtained from the experiment represented in Figure 3-19. The 
fractions were pooled and then diluted with the binding buffer without imidazole to give 
the pooled fractions containing imidazole a final concentration of approximately 0.01 M. 
The sample was then reloaded on the HisTrap column which was pre-equilibrated with 
4   CV of Buffer A which also used to wash the column after sample application. The 
elution gradient was between Buffer A against Buffer with 0.1 M imidazole. In this 
instance VP6 did completely bind to the Ni2+ resin and was present in the fractions 
collected during the elution gradient (Figure 3-20), but bacterial cellular proteins were 
still detected along with VP6. 
Fractions from the experiment represented in Figure 3-20 were pooled, and imidazole 
concentration was diluted to approximately 0.01 M using Buffer A with no imidazole. 
The diluted sample was applied to a HisTrap column pre-equilibrated with Buffer A, and 
then the column was washed with the same buffer and eluted with a modified elution 
volume that was increased from 10   CV to 15   CV, and the elution gradient was 
shortened from 0.2 M to 0.1 M imidazole, this was an attempt to further separate the 
proteins during elution. Fractions A/3 to A/13 contained a low, but pure yield of VP6 
(Figure 3-21). The protein yield was observed to be low and was repeated with a culture 
volume of 1300 ml instead of 500 ml in previous purifications. 
KRX cells were grown and induced using optimised expression conditions described in 
section 3.1. Supernatant containing VP6 was obtained from KRX cells using the method 
described in section 2.3. The supernatant was loaded onto a DEAE column pre-
equilibrated with Buffer B. An elution gradient from 0.08 M up to 0.2 M sodium chloride 
was used to elute VP6. After a 4   CV wash with Buffer B VP6 was present fractions 
A/7 to A/9 (Figure 3-22).  
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Figure 3-19: Affinity (HisTag) chromatography purification of VP6 using a sodium 
phosphate buffer and a gradient elution from 0.01 M up to 0.2 M imidazole 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicating the lane 
“MWM” which represents the molecular weight marker in kDa. The lane marked “PF” represents 
the pooled fractions containing VP6 from the anion exchange chromatography represented in 
Figure 3-18. The lane labelled “FT” represents the flow-through protein sample that did not bind, 
but passed through the column during sample loading. The lane marked “Wash” represents the 
proteins washed from column during the wash step. Selected fractions between “A/2” to “A/8” 
represent the fractions that were collected during the elution gradient from 0.01 M up to 0.2 M of 
imidazole.  
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Figure 3-20: Affinity (HisTag) chromatography purification of VP6 using a sodium 
phosphate buffer and a gradient elution from 0.01 M up to 0.1 M imidazole 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicating the lane 
“MWM” which represents the molecular weight marker in kDa. The lane marked “PF” represents 
the pooled fractions containing VP6 from affinity chromatography experiment (Figure 3-19). The 
lane marked “Wash” represents the proteins washed from column during the wash step. 
Selected fractions between “A/”1 to “A/7” represents the fractions that were collected during the 
elution gradient from 0.01 M up to 0.1 M imidazole concentration.  
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Figure 3-21: Affinity (HisTag) chromatography purification of VP6 using a sodium 
phosphate buffer and a 15 column volumes gradient elution from 0.01 M up to 0.1 M 
imidazole 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicates the lane 
“MWM” which represents the molecular weight marker in kDa. The lane marked “PF” represents 
the pooled fractions containing VP6 from the previous HisTag VP6 purification. The lane marked 
“Wash” represents the proteins washed from column during the wash step. The selected 
fractions between “A/1” to “A/13” represents the fractions that were collected during the elution 
gradient from 0.01 M up to 0.1 M imidazole concentration.  
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Figure 3-22: Anion (DEAE Sepharose) exchange chromatography partial purification of 
VP6 using a gradient elution of up to 0.2 M sodium chloride, trial 2 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicates the lane 
“MWM” which represents the molecular weight marker in kDa. The lane marked “S” represents 
the soluble proteins obtained from the supernatant of the cell lysate loaded onto the column. 
The lane marked “Wash” represents the proteins washed from column during the wash step. 
Selected fractions between “A/3” and “A/15” represent fractions that were collected during the 
elution gradient from 0.08 M up to 0.2 M sodium chloride.  
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The VP6 containing fractions were pooled, and imidazole was added to a final 
concentration of 0.01 M, before being applied to a HisTrap column which was pre-
equilibrated with Buffer A. The column was washed with 4   CV of the same buffer; 
VP6 was completely bound to the column resin and was eluted during the elution 
gradient (Figure 3-23) spanning from 0.01 to 0.1 M imidazole concentration. 
Fractions A/2 to A/11 were pooled, diluted with Buffer A to reduce the imidazole 
concentration to approximately 0.01 M, and then again loaded on a HisTrap column to 
ensure that VP6 reached a higher purity level. The purification was performed with the 
same conditions as the previous affinity chromatography experiment, but in this 
instance the elution gradient was reduced to 0.055 M which was calculated by deriving 
55% (the point on the elution gradient where VP6 was eluted) from 0.1 M imidazole 
(final concentration of imidazole on the elution gradient), the elution volume was 
increased from 15 to 20   CV. Fractions A/4 to A/11 contained more VP6 and no 
contaminant proteins (Figure 3-24). 
In this study it was observed that the HisTrap column was not capable of binding all of 
the VP6 and the cellular proteins present in the supernatant, most of the proteins are 
washed off the column (Figure 3-8, Figure 3-9 and Figure 3-19). Thus, a 20 ml HisPrep 
column was used in experiments shown in Figures 3-23 and Figure 3-24.  
Initially the HisTag affinity chromatography was not efficient in separating VP6 from 
other contaminating bacterial cellular proteins, but it was found that by narrowing the 
final gradient elution from 0.2 M to 0.1 M imidazole concentration, and increasing the 
elution volume from 10 to 20   CV helped promote separation of VP6 from the 
contaminating proteins (Figure 3-24) 
VP6 obtained from the affinity chromatography fractions contain 3 M urea, and 
approximately 0.05 M imidazole when pooled together, these chemicals affect the 
structure and absorbance reading of the protein, thus the protein has to be buffer 
exchanged into Buffer D prior to concentration determination and structural 
determination tests. The fractions containing pure VP6 were pooled, concentrated and 
loaded onto a HiPrep (50 ml) desalting column from GE, which was pre-equilibrated 
with Buffer D  
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Figure 3-23: Affinity (HisTag) chromatography purification of VP6 using a sodium 
phosphate buffer and a 15 column volume gradient elution from 0.01 M up to 0.1 M 
imidazole, trial 2 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicating the lane 
“MWM” which represents the molecular weight marker in kDa. The lane marked “PF” represents 
the pooled fractions containing VP6 from the ion exchange chromatography (Figure 3-22). The 
lane marked “Wash” represents the proteins washed from column during the wash step. 
Selected fractions “A/1” to “A/6” represent the fractions that were collected during the elution 
gradient from 0.01 M up to 0.1 M imidazole concentration. 
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B. 
Figure 3-24: Affinity (HisTag) chromatography purification of VP6 using a sodium phosphate buffer and a 20 column 
volumes gradient elution from 0.01 M up to 0.055 M imidazole 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), conductivity (red line) and elution gradient 
(green line). B. SDS-PAGE gel indicates the lane “MWM” which represents the molecular weight marker in kDa. The lane marked 
“PF” represents the pooled fractions containing VP6 from the HisTag affinity chromatography (Figure 3-23). Selected fractions 
between “A/1” to “A/16” represent fractions that were collected during the elution gradient from 0.01 M up to 0.055 M imidazole 
concentration. 
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The proteins that passed through the column were collected in 5 ml fractions, and then 
electrophoresed on a SDS-PAGE gel (Figure 3-25) in order to identify fractions 
containing VP6. Fractions A/4 and A/5 were pooled, then used for concentration 
determination and structural characterisation. 
 
3.3. Protein concentration determination 
Analysis of the protein sample was conducted by scanning across an absorbance 
spectrum ranging from 340 nm to 220 nm to assess concentration and purity of the 
purified VP6. The A260 was found to be higher than A280 indicating that there were 
nucleotides present in the VP6 sample (Figure 3-26), the A280 reading was used to 
determine the concentration of the purified VP6 using the formula described in section 
2.13 which gave 0.76 µM VP6 in 5 ml Buffer D. This meant that a 1000 ml culture 
yielded 0.17 mg of VP6. The concentration calculated for VP6 is low because of the low 
absorbance reading at 280 nm.  
 
3.4. Purification of VP6 with removal of nucleotides 
Induced KRX cells were resuspended in Buffer E which has a lower sodium phosphate 
and lower sodium chloride concentration which prevents interferences with absorbance 
readings during UV CD analysis. The Buffer E used resuspend the proteins prior to 
purification contains 0.1 g/ml of DNase 1; 0.05 M magnesium chloride and 0.0001 M 
phenylmethane sulfonyl fluoride (PMSF) which binds and inhibits protease activity, thus 
preventing protein degradation by proteases. 
The cells were sonicated, then centrifuged to separate the supernatant from pellet. The 
supernatant was applied to a DEAE anion exchange column that was pre-equilibrated 
with Buffer E. The column was then washed with 5   CV of Buffer E before initiating a 
gradient elution starting at 0.02 M sodium chloride and ending with 0.3 M sodium 
chloride. VP6 was successfully bound to the column, with fractions A/9 to A/16 having 
the highest amount of VP6 (Figure 3-27).  
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Figure 3-25: Buffer exchange using HiPrep desalting column 
SDS-PAGE gel indicates the lane “MWM” which represents the molecular weight marker in kDa. 
The lane marked “PF” represents the pooled fractions containing VP6 from the HisTag affinity 
chromatography (Figure 3-24). The selected fractions between “A/3” to “A/7” represents the 
fractions that were collected after being applied on the HiPrep desalting column. Fractions “A/4” 
and “A/5” contain buffer exchanged VP6.  
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Figure 3-26: Absorbance spectrum of purified rotavirus VP6 
The absorbance spectrum of VP6 was set from 340 nm to 220 nm. The spectrum was collected 
using 0.76 µM of VP6 buffer exchanged into 0.05 M sodium phosphate buffer, pH 7.04, 
containing 0.08 M sodium chloride over the length of 1 cm. The spectrum was collected at 1 nm 
per 0.5 s. 
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A. 
 
B. 
Figure 3-27: Partial purification of VP6 using anion (DEAE Sepharose) exchange 
chromatography with a gradient elution of up to 0.3 M sodium chloride 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicating the lane 
“MWM” which represents the molecular weight marker in kDa. The lane marked “S” represents 
the soluble proteins obtained from the supernatant of the cell lysate loaded onto the column. “P” 
represents pelleted proteins precipitated from the cell lysate. The lane labelled “FT” represents 
the flow-through protein sample that did not bind, but passed through the column during sample 
loading. The lane marked “Wash” represents the proteins washed from column during the wash 
step. “Regen” represents regeneration which signifies the protein collected during 1 M sodium 
chloride column wash. Selected fractions between “A/5” and “A/15” represent fractions that were 
collected during the elution gradient from 0.02 M up to 0.3 M sodium chloride.  
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The fractions containing VP6 were pooled, concentrated, buffer exchanged to Buffer E 
containing 0.01 M imidazole, then loaded onto a HisPrep column pre-equilibrated with 
Buffer E containing 0.01 M imidazole, then VP6 was eluted with gradient of between 
Buffer E and Buffer E containing 0.055 M imidazole. Fractions A/1 to A/23 contained 
VP6 with only A/13 to A/23 containing pure VP6 (Figure 3-28 B). 
Pure protein was obtained in fractions A/13 to A/23 which were then pooled, 
concentrated and buffer exchanged to Buffer E using a 5 ml desalting column. Using the 
A280 reading (Figure 3-29), from the absorbance spectrum VP6 concentration was 
calculated to be 1 µM (0.22 mg of VP6 from 1000 ml cell culture), A260/A280 ratio was 
0.91, which is lower than that obtained from the spectrum represented in Figure 3-26, 
which was 1.43. This indicated that there were less nucleotides present. 
 
3.5. Structural characterisation of purified VP6 
Far-UV CD was used on a 1 µM protein concentration in Buffer E with a path length of 1 
mm. The CD spectra of VP6 (Figure 3-30 A), shows typical spectral characteristics of 
proteins that contains α-helices. This is signified by the trough at 208 nm and the trough 
at 222 nm that is also due to α-helices, counter-acted by the increase in ellipticity due to 
the presence of β-sheets (Sreerama & Woody, 2003). Far-UV CD can be used to 
assess changes in the protein’s secondary structure when determining the stability of 
VP6 in different temperature, urea and sodium chloride concentrations. 
Intrinsic fluorescence was used to identify the local tertiary environment around the 
tryptophan residues of the VP6 protein which can also provide a useful way of 
monitoring local conformational changes in the protein (Lakowicz, 2006). The RV VP6 
has 5 tryptophan residues with 2 located on the β-sheet domain and three in the α-
helical domain (Figure 1-4) (Zhao et al. 2011). The fluorescence intensity was recorded 
at 340 nm when excited at wavelengths of 295 nm and at 280 nm (Figure 3-30 B). 
  
66 
 
 
A.  
 
B. 
 
Figure 3-28: Affinity (HisTag) chromatography purification of VP6 using a sodium 
phosphate buffer and a 20 column volumes gradient elution from 0.01 M up to 0.055 M 
imidazole, trial 2 
A. The elution chromatographic profile illustrates the absorbance at 280 nm (blue line), 
conductivity (red line) and elution gradient (green line). B. SDS-PAGE gel indicating the lane 
“MWM” which represents the molecular weight marker in kDa. The lane marked “PF” represents 
the pooled fractions containing VP6 from the ion exchange chromatography (Figure 3-29). The 
lane labelled “FT” represents the flow-through protein sample that did not bind, but passed 
through the column during sample loading. The lane marked “Wash” represents the proteins 
washed from column during the wash step. “Regen” represents regeneration which signifies the 
protein collected during 0.5 M imidazole column wash. The selected fractions between “A/1” to 
“A/16” represents the fractions that were collected during the elution gradient from 0.01 M up to 
0.055 M imidazole concentration.  
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Figure 3-29: Absorbance spectrum of purified rotavirus VP6 
Spectrum shown represents the absorbance of VP6 over wavelengths of 340 to 220 nm. The 
spectrum was collected using 1 µM VP6 in 0.02 M sodium phosphate buffer, pH 7.04, 
containing 0.02 M sodium chloride over a 1 cm pathlength. The spectrum was collected at 1 nm 
per 0.5 s. 
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Figure 3-30: Native VP6 assessed by far-UV CD and Fluorescence 
A. Far-UV circular dichroism spectrum of the native secondary structure of VP6, and B. 
fluorescence emission spectrum of rotavirus VP6 excited at 280 nm (red), and excited at 295 
nm (blue). Both spectra were collected using 1 µM of VP6 in 0.02 M sodium phosphate buffer, 
pH 7.04, containing 0.02 M sodium chloride.  
-20
-15
-10
-5
0
5
10
15
190 200 210 220 230 240 250
[θ
] 
(d
e
g.
cm
2 .
d
m
o
l-1
) 
wavelength (nm) 
A 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
280 330 380 430 480
Fl
u
o
re
sc
e
n
ce
 in
te
n
si
ty
 (
A
rb
it
ar
y 
u
n
it
s)
 
Wavelength (nm) 
B 
69 
 
3.6 Thermal unfolding 
Thermal unfolding was assessed using far-UV CD to monitor changes in the secondary 
structure of VP6 when exposed to 0.02 M sodium chloride (Appendix B i), and 0.2 M 
sodium chloride (Appendix B ii). VP6 that was in 0.02 M sodium phosphate buffer, pH 
7.04 containing 0.02 M sodium chloride lost its α-helical properties as the temperature 
increased above 50°C; this is indicated by the increase in absorbance at 222 nm (Kelly 
et al. 2005; and Corrêa & Ramos, 2009). At 90°C VP6 displayed a loss in structure and 
therefore the value shifted to a lower minimum at 200 nm (Appendix B i) (Corrêa & 
Ramos, 2009). 
Ellipticity at 222 nm versus temperature displayed a sigmoidal shape showing no 
change in the α-helical domain while between 20°C to 40°C, but showed an increase in 
ellipticity when temperature was increased above 40ºC (Figure 3-31 A red). There was 
a loss in the secondary structure particularly in the α-helices. There is a gradual loss of 
secondary structure between 40°C to 70°C displayed by an increase in ellipticity at 222 
nm. VP6 in Buffer E displayed an increase in ellipticity at 222 nm indicating a loss in α-
helical structure, but with less defined intermediate structures (Figure 3-31 A blue). The 
VP6 sample was diluted at a ratio of 1:1 with Buffer E, yielding a final concentration of 
0.76 µM. Using the thermal unfolding data, an intrinsic fluorescence at 340 nm versus 
temperature graph was derived which indicated that the fluorescence intensity 
decreased as the temperature was increased from 20ºC to 40ºC (Figure 3-31 B blue). 
An intrinsic fluorescence versus wavelength graph shows that fluorescence intensity at 
340 nm decreased as the temperature increased from 20°C to 90°C (Appendix C i).  
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Figure 3-31: Thermal unfolding of VP6 monitored by far-UV CD and intrinsic fluorescence 
A. Far-UV CD heat unfolding curve assessed using 1 µM VP6 in 0.02 M sodium phosphate 
buffer, pH 7.04 containing 0.02 M sodium chloride (blue). Heat unfolding curve of 0.35 µM VP6 
in 0.02 M sodium phosphate buffer, pH 7.04 containing 0.2 M sodium chloride (red). Both the 
far-UV spectra were monitored at 222 nm during thermal ramping from 20°C to 90°C 
B. Intrinsic fluorescence thermal unfolding was monitored using 0.78 µM protein in 0.02 M 
sodium phosphate pH 7.04 containing 0.02 M sodium chloride (blue), a thermal unfolding 
spectra of 0.35 µM VP6 in 0.02 M sodium phosphate pH 7.04 containing 0.2 M sodium chloride 
(red). Both the fluorescence emission spectra were monitored at 340 nm during thermal 
ramping from 20°C to 90°C.  
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These findings of reduction in fluorescence intensity are associated with quenching 
most probably by peptide bonds (Lakowicz, 2006), histidine was also reported to be 
capable of quenching. 
Thermal unfolding was monitored using intrinsic fluorescence with 0.35 µM protein (0.08 
mg VP6 from 1000 ml cell culture) in Buffer E containing 0.2 M sodium chloride. The 
fluorescence intensity at 340 nm dropped to its lowest when temperature reached 37ºC, 
then continued to rise until 90ºC (Figure 3-31 B red). The temperature versus intrinsic 
fluorescence emission graph indicates that there was a blue shift in the emission peak 
from 340 nm at 20ºC to 319 nm at 90ºC (Appendix C ii). 
VP6 was allowed to cool down and refold back to its tertiary structure at 20°C. The 
emission intensity was recorded to be 0.78 (Figure 3-32 B blue) which shows that the 
structural changes that promoted quenching were still favoured. 
Structural analysis of VP6 was performed in the presence of 0.2 M sodium chloride to 
evaluate any difference in VP6’s structure and conformational stability on exposure to 
that sodium chloride concentration. 
The thermally unfolded VP6 sample used for CD thermal denaturation assessment was 
allowed to return to room temperature then again assessed by far-UV CD to monitor the 
refolded state of the protein. VP6 refolded back into its native state, this was indicated 
by an ellipticity minima at 208 nm (Figure 3-32 A red). The ellipticity at 217 nm to 222 
nm is constant indicating the counter absorptive action of decrease in ellipticity caused 
by the α-helices and the increase in ellipticity caused by β-sheet. 
Intrinsic fluorescence was used to monitor tertiary structural changes during heat 
denaturation, the emission of light by intrinsic fluorophores is dependent on the local 
tertiary environment of the protein (Lakowicz, 2006). 
 
3.7 Effect of urea and sodium chloride on the secondary and tertiary structure of 
VP6 
A 3 M urea concentration was used during affinity HisTag chromatography to ensure 
that the HisTag was not buried within the protein. The 3 M urea was preferred as to 
prevent complete unfolding of the protein.  
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Figure 3-32: Reversibility of thermally unfolded VP6 monitored by Far-UV circular 
dichroism and intrinsic fluorescence 
A. The far-UV CD spectrum for the native folded form of VP6 (blue), and the spectrum for the 
refolded form of the protein after thermal denaturation at 90ºC (red). The spectra were collected 
using 1 µM protein in 0.02 M sodium phosphate buffer, pH 7.04, containing 0.02 M sodium 
chloride. B. Intrinsic fluorescence emission spectrum for the native VP6 form (blue), and 
refolded form of VP6 (red), after a thermal denaturation at 90ºC. Fluorescence spectra for VP6 
refolded after thermal unfolding up to 90°C using 0.78 µM protein in 0.02 M sodium phosphate 
buffer, pH 7.04, containing 0.02 M sodium chloride.  
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Far-UV CD and intrinsic fluorescence were used to monitor the secondary and tertiary 
structural changes caused by 3 M urea. 
Far-UV CD revealed that the mean residue ellipticity at 222 nm still maintained a high 
negative value (Figure 3-33 A green) implying that the β-sheets and α-helices of VP6 
were not unfolded by 3 M urea.  
Intrinsic fluorescence spectra of VP6 with 3M urea displayed a maximum at 340 nm 
(Figure 3-33 B green), thus showing no red-shift that is typically observed when 
fluorophores are shifted from proteinic to aqueous environment. Instead there is 
quenching indicating that there was structural rearrangements that brought the 
quencher close to the tryptophan residue. 
There was no observable difference in VP6s secondary structure when exposed to 0.02 
M sodium chloride from when it was exposed to 0.2 M sodium chloride (Figure 3-33 A). 
The presence of 0.2 M sodium chloride caused tertiary structural rearrangements that 
promoted quenching (Figure 3-33 B red) as compared to a higher fluorescence 
emission intensity when VP6 was exposed to a lower sodium chloride concentration of 
0.02 M (Figure 3-33 B blue). 
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Figure 3-33: Effect of urea and sodium chloride on the secondary and tertiary structure of 
VP6 
A. Far-UV circular dichroism spectra using 0.40 µM native VP6 in 0.02 M sodium phosphate 
buffer, pH 7.04, containing 0.02 M sodium chloride, (blue); 0.35 µM VP6 in 0.02 M sodium 
phosphate buffer at pH 7.04, containing 0.2 M sodium chloride (red), and 0.35 µM VP6 in 0.02 
M sodium phosphate buffer at pH 7.04, containing 0.02 M sodium chloride and 3 M urea 
(green). B. Intrinsic fluorescence spectra of 0.40 µM native VP6 in 0.02 M sodium phosphate 
buffer, pH 7.04, containing 0.02 M sodium chloride (blue); 0.35 µM VP6 in 0.02 M sodium 
phosphate buffer at pH 7.04, containing 0.2 M sodium chloride (red), and 0.35 µM VP6 in 0.02 
M sodium phosphate buffer at pH 7.04, containing 0.02 M sodium chloride and 3 M urea 
(green).  
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Chapter 4: Discussion 
Over-expressed soluble VP6 was highly expressed in KRX cells when induced with 
0.0001 M IPTG and 0.05% L-rhamnose, for a period of 6 h while incubated at 25°C 
(Figure 3-2). BL21 cells proved to be efficient in expressing VP6 at a higher yield than 
KRX cells, but the ratio of soluble to insoluble VP6 was low. The expression efficiency 
of proteins by the KRX cells was also described by Hartnett et al. (2006) who found that 
these cells express soluble active enzyme (firefly luciferase) when compared to the 
BL21 cells, which express non-functional, misfolded enzymes with low enzyme activity. 
KRX cells have a suppressed T7 RNA polymerase expression which is under the 
control of rhaPBAD promoter induced by L-rhamnose (Studier & Moffat, 1986; Narita & 
Tokuda, 2009). This provides a more controllable expression of proteins by reducing the 
rate of expression, which in turn prevents protein from misfolding into inclusion bodies 
(Villaverde & Carrio, 2003; Sørensen & Mortensen, 2005). A study by Zhao et al. (2011) 
used BL21 cells with a pET vector to express RV VP6 which used insoluble, pelleted 
protein as no soluble proteins were obtained, Bredell et al. (2016) compared the 
expression of RV VP6 in E.coli BL21 cells to yeast cells which reported that the yeast 
cells expressed soluble protein while the BL21 cells failed to accomplish this. Esteban 
et al. (2013) carried out a study to express RV VP6 using Lactococcus lactis which 
failed to express VP6 in a soluble form. Eukaryotic human embryonic kidney cells 
proved to be efficient in expressing soluble non-degraded VP6 compared to the insect 
cell-baculovirus system which had a higher VP6 yield in insoluble form (da Silva et al. 
2012) 
 
The use of a denaturant (Seth et al. 2017) while purifying a protein may vary the 
outcome of the experiment whereby the charged regions are fully exposed allowing for 
binding onto the resin. This prevents aggregation of the proteins due to exposure to a 
pH environment outside its stable pH range (Chi et al. 2003)a. 
Failure of VP6 to be eluted off a weak anion exchanger column (DEAE Sepharose) after 
exposing the protein to sodium phosphate buffer at pH 5 reveals that VP6 was not 
protonated by the buffer with a pH that is a unit lower than its pI (6.65), or it could be 
that the expressed VP6 had a different pI from the theoretical pI of 6.42. 
76 
 
Rotavirus VP6 is affected by pH and ionic strength as shown by Lepault et al. (2001). A 
MOPS buffer was used to purify VP6 using an anion (DEAE Sepharose) exchanger 
column. A 0.03 M MOPS buffer has an ionic strength of 0.99. Lepault et al. (2001) 
indicated that RV VP6 is affected by the ionic strength of the solution and, thus, a buffer 
with a greater ionic strength than sodium phosphate (which is 0.42) was used in order to 
increase the stability of the protein. This was to eliminate the formation of small protein 
aggregates that occur when exposed to a buffer with an ionic strength below 0.1 
(Lepault et al. 2001). RV VP6 has been shown to exist as tubular structures when 
exposed to an aqueous environment at pH 6 to 8 with a buffer with an ionic strength 
above 1. Purification using a MOPS buffer and a DEAE column did not produce good 
results (Figure 3-11). The reason the MOPS buffer was not ideal for VP6 purification on 
a DEAE column was because there were proteins that were found to be present at 
different elution fractions in the gradient, and those proteins had a similar size as VP6 
when compared against the MWM. This indicates that VP6 existed in different structural 
conformations when it was suspended in 0.03 M MOPS buffer. The effect of ionic 
strength having an effect on VP6’s conformation is seen in Figure 3-33 B where the 
presence of 0.2 M sodium chloride caused tertiary structural rearrangements that 
promoted quenching (Figure 3-33 B red) as compared to a higher fluorescence 
emission intensity when VP6 was exposed to a lower sodium chloride concentration of 
0.02 M (Figure 3-33 B blue).  
A thermal unfolding study of VP6 was performed to monitor the structural behaviour of 
VP6 in increasing temperature when exposed to 0.02 M sodium chloride and when 
exposed to a higher sodium chloride concentration of 0.2 M. When the temperature was 
raised from 20°C to 37°C fluorescence emission signal was gradually reduced in 
proteins exposed to 0.02 M and 0.2 M of sodium chloride, this indicated that there were 
conformational changes that promoted quenching (Appendix C i and Appendix C ii). 
When the temperature was further increased above 50°C, the VP6 exposed to 0.2 M of 
sodium chloride started displaying an increase in its fluorescence emission intensity, 
which indicated that there were conformational changes in the protein that caused 
quenchers to move away from the fluorophores, the fluorescence emission continued to 
rise until 90°C was reached (Appendix C ii). There was also a blue-shift when the 
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temperature was increased from 57ºC to 90ºC which shows that there were tertiary 
structural changes that occurred, which further buried the fluorophores within the protein 
(Appendix C ii). The VP6 exposed to 0.02 M of sodium chloride only experienced a 
further drop in fluorescence emission until 90°C was reached, with no shift in the 
emission peak from all the spectrum collected (Appendix C i). 
Purification using sodium phosphate at pH 7.04 improved the purity of VP6, even 
though the protein was not pure there was better isolation of the target protein whereby 
it was separated from lower molecular weight proteins (Figures 3-13; 3-17, and Figure 
3-18). It was also observed that VP6 purification using HisTag affinity chromatography 
mostly separated proteins with a higher molecular weight from VP6 (Figure 3-9).  
A dual purification procedure was adopted with anion exchange chromatography used 
as the first purification technique then followed by HisTag affinity chromatography. 
When a protein sample containing VP6 was applied to a HisPrep affinity 
chromatography column, it was observed that VP6 was found in the fraction containing 
unbound proteins from the column wash, indicating that it did not bind to the column 
(Figure 3-8). The 3 M urea appeared to affect the tertiary structure of VP6 as seen in 
Figure 3-33 to facilitate exposure of the histidine residues and allow binding of VP6 to 
the HisPrep column. 
When VP6 was partially purified using DEAE anion exchange chromatography (Figure 
3-27) it no longer required to be unfolded using urea in order to bind to the HisPrep 
affinity chromatography column (Figure 3-28). This was suspected to have occurred 
because of the decrease in competing for binding sites due to the decrease in bacterial 
cellular proteins and the increased in resin bed. 
 
Far-UV CD and intrinsic fluorescence were used as secondary and tertiary structural 
probes for VP6. The far-UV CD readings agree with findings by Zhao et al. (2011), that 
illustrated that VP6 has the highest negative value at 208 nm (Figure 3-30 A), and the 
minimum at 222 nm value that was counteracted by the presence of β-sheets (Figure 1-
4) (Kelly & Price, 2000). 
A study by Zhao et al. (2011) who characterised RV VP6 found that VP6 displayed a 
fluorescence emission peak of 341 nm which is in agreement with the fluorescence data 
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from the current study (Figure 3-30 B). Appendix D shows a globular structure of a VP6 
monomer with the five tryptophan residues buried within the protein, hence, explaining 
why the emission peak was recorded at a wavelength of 340 nm (Lakowicz, 2006). 
A 0.2 M sodium chloride concentration was used to elute VP6 off a DEAE column, this 
condition was assessed to observe the structural (secondary or tertiary) effects that it 
has on VP6. There was no observable difference in VP6’s secondary structure when 
exposed to 0.02 M sodium chloride from when it was exposed to 0.2 M sodium chloride 
(Figure 3-33 A), but ellipticity at 222 nm monitoring thermal unfolding showed that there 
were two distinct intermediate phases to the secondary structure that occur at 
temperatures 20ºC to 40ºC, and 70ºC to 90ºC (Figure 3-31 A red). Thermal unfolding of 
VP6 in 0.2 M sodium chloride did not display distinct intermediate secondary structure 
phases (Figure 3-31 A blue); this is because a protein spectrum from a lower protein 
concentration has a low signal making it difficult to identify the intermediate phases on 
the spectra. VP6 was able to refold back to its secondary structure when cooled to 20ºC 
after exposure to 90ºC (Figure 3-32 A), but the tertiary structure did not return to its 
native conformation when assessed using intrinsic fluorescence (Figure 3-32 B). Chi et 
al. (2003)b stated that certain proteins can permanently aggregate and not refold after 
being thermally denatured. During thermal denaturation VP6 displayed a reduction in 
fluorescence emission at a peak of 340 nm, when heated up to 90°C (Appendix C i); 
whereas it is described that during protein unfolding (chemical or thermal), an intrinsic 
fluorescence spectral peak experiences a red-shift; this occurs when the fluorophores 
shift from proteinic to the aqueous environment (Lakowicz, 2006). This gives the 
impression that VP6 was not unfolding with the increase in temperature, but merely 
being quenched. Tryptophan emission can be affected by quenchers that include 
nearby peptide bonds, which undergo alignment changes that occur because of “small 
motions” in amino acid side chains or protein backbone. Reduced emission intensity by 
tryptophan may come as a result of quenching caused by small motions in amino acid 
side chains or backbone (Lakowicz, 2006). The presence of two histidine tags 
expressed on either side of VP6 can be affected by these “small motions”, allowing the 
tags to move close to the tryptophan residues, and acting as quenchers. 
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Appendix C ii shows that there was a blue-shift in the emission intensity when thermal 
unfolding was monitored in the presence of 0.2 M sodium chloride. The emission 
intensity was highest at 320 nm when the temperature reached 90ºC, this emission 
intensity is characterised by the primary fluorophore tryptophan being placed in a less 
aqueous environment, (Lakowicz, 2006). The shift in the emission peak to a lower 
wavelength was not observed when VP6 was in 0.02 M sodium chloride (Appendix C i), 
indicating that sodium chloride had an influence in the tertiary conformation of the 
protein during changing temperatures. 
Far-UV CD spectra of VP6 exposed to 3 M urea did not affect the secondary structure 
of the protein (Figure 3-33 A green) but changes in the tertiary structure assessed by 
intrinsic fluorescence indicated that the emission maximum on the intrinsic fluorescence 
spectrum of VP6 in 3 M urea was still observed at 340 nm with a lower emission unit of 
1.34 (Figure 3-33 B green), which comes as a result of low VP6 concentration which 
was calculated to be 0.4 µM when assessing the native protein, and 0.35 µM when 
assessing the denatured VP6. Addition of 3 M urea did not affect the secondary 
structure (Figure 3-33 A), and the tertiary structure (Figure 3-33 B) of VP6.  
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Chapter 5: Conclusion 
The goal of this study was to develop a swift and cost effective method of expressing 
soluble RV VP6. Purification proved to be difficult when binding VP6 to a DEAE 
Sepharose column using MOPS buffer. A phosphate buffer was used to purify VP6 on 
an anion exchange column along with HisTag affinity chromatography. The expressed 
VP6 was found to have a correctly folded secondary structure characterised by an 
ellipticity minima at 208 nm, and an ellipticity value that was affected by the presence of 
the β-sheet making a constant reading between 222 nm and 215 nm, as determined by 
Far-UV CD. Intrinsic fluorescence of VP6 revealed that the protein had buried 
tryptophan residues as indicated by its emission peak at 340 nm. High sodium chloride 
concentrations of 0.2 M had no effect on VP6’s secondary structure, but it altered the 
tertiary structure of the protein by causing motions that caused quenchers to move 
closer to the tryptophan residues, thus decreasing the emission signal (Figure 3-33 B 
red). Exposing VP6 to increasing temperatures of up to 90ºC when the protein was in a 
buffer containing a sodium chloride concentration of 0.02 M indicated that VP6 was 
resistant to unfolding at those temperatures, but the emission signal was reduced 
showing that it had undergone structural changes that caused quenchers to move 
closer the fluorophores (Figure 3-31 B blue; & Appendix C i). When VP6 was In the 
presence of 0.2 M sodium chloride, the emission from the fluorophores was gradually 
decreased, but when the temperature reaches 50ºC there was an increase in the 
emission intensity indicating that there were structural changes that caused the 
fluorophores and quenchers to move away from each other (explained by the gradual 
increase in emission signal), this was also accompanied by further burying of the 
tryptophan residues explained by the shift in emission peak to shorter wavelengths 
(Figure 3-31 B red; & Appendix C ii). This indicated that there are variations in VP6’s 
amino acids that are exposed depending on the ionic strength of the buffer, this further 
explains why successful binding of VP6 to a DEAE Sepharose column was achieved 
when using a phosphate buffer, but failed to bind when a higher ionic strength MOPS 
buffer was used. 
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Chapter 7: Appendices 
 
 
 
 
 
 
 
 
 
 
 
Appendix A: SDS-PAGE analysis of VP6 
The calibration curve was used to calculate VP6’s molecular weight which was found to be 
50.12 kDa based on the straight line fit y = -0.0101x + 2.0735. This analysis is an example of 
how VP6’s size was calculated from all SDS-PAGE gels. 
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Appendix B: Circular dichroism during thermal unfolding of VP6 
i. Far-UV circular dichroism spectrum recorded from 20ºC to 90ºC on 1 µM VP6 in 0.02 M 
sodium phosphate buffer, pH 7.04 containing 0.02 M sodium chloride. ii. Far-UV circular 
dichroism spectrum recorded from 20ºC to 90ºC on 0.35 μM VP6 in 0.02 M sodium phosphate 
buffer, pH 7.04 containing 0.2 M sodium chloride.  
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Appendix C: Fluorescence thermal unfolding of VP6 excited at 280 nm 
Individual temperature spectra are selectively indicated between 20°C and 90°C, with each 
temperature having a fluorescence spectra read from 500 nm to 280 nm. i. Data was collected 
using 0.78 µM VP6 in 0.02 M sodium phosphate buffer, pH 7.04 containing 0.02 M sodium 
chloride. ii. Data was collected using 0.35 µM VP6 in 0.02 M sodium phosphate buffer, pH 7.04 
containing 0.2 M sodium chloride.  
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Appendix D: Globular diagram of rotavirus VP6 
The 3-D globular structure of a rotavirus VP6 monomer was generated as part of the current 
study. VP6 comprises of five tryptophan residues (blue globules) (Mathieu et al. 2001). Image 
was generated using Swiss PDB Viewer (version 4.1.0) [Guex and Peitsch, 1997], from a 
rotavirus VP6 protein, PDB code: 1QHD. 
